Skip to main content

Where our analysis comes from

The source hierarchy our analysis follows — peer-reviewed pharmacology first, regulators as legal context.

Regimens™ evaluates everything you take — medications, supplements, herbs, foods, peptides, recreational substances — and flags interactions, contraindications, timing conflicts, and depletion patterns. The quality of that analysis is only as good as its sources.

This page exists because most AI wellness tools won’t tell you where their information comes from, and we think you deserve to know.

01.

Our principle: science first, regulation as context

When peer-reviewed pharmacology research and a national regulator’s position diverge, we lead with the science.

National regulators like the FDA, DEA, MHRA, and EMA serve essential functions — they manage legal status, approve indications, and protect public safety. But regulatory frameworks lag the scientific literature, sometimes by decades. The 2002 FDA consumer advisory on kava, for example, persists in the regulatory record despite subsequent research substantially reframing those original case reports — and despite the 2020 Codex Alimentarius standard that recognizes traditionally prepared aqueous kava as a food.

When MDMA-assisted therapy showed Phase 3 efficacy for PTSD in 2021, the DEA’s Schedule I designation didn’t move. The science had advanced; the regulatory framework hadn’t.

Citing regulatory bodies as the primary scientific authority would mean accepting that latency as truth. We don’t.

Instead, our analysis follows a tiered hierarchy that prioritizes the underlying evidence and treats regulatory positions as legal-status context.

02.

The source hierarchy

The tiers below are the universe of evidence the analyzer is built to reason within. Tier 1 leads; each lower tier is cited for what it is authoritative on, not as a substitute for stronger evidence. National regulators close the hierarchy at Tier 6 as legal context, not scientific authority.

Tier 1 — Peer-reviewed pharmacology and clinical research

This is where the science actually lives. Our analysis prioritizes:

PubMed-indexed primary research

Specifically randomized controlled trials, systematic reviews, and meta-analyses from journals indexed in MEDLINE.

pubmed.ncbi.nlm.nih.gov →

Cochrane systematic reviews

Cochrane is the gold standard for evidence synthesis in medicine — independent, methodologically rigorous, and updated continuously. The Cochrane Complementary Medicine field publishes systematic reviews on integrative and complementary modalities under the same methodological standards.

cochrane.org →

Established pharmacology references

Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Stockley’s Drug Interactions, and other clinical references that practicing pharmacologists actually use.

Preprint servers (bioRxiv, medRxiv)

When relevant emerging research hasn't yet completed peer review, we reference it explicitly as preliminary — not as established consensus.

DrugBank

A comprehensive online drug knowledgebase maintained by the University of Alberta and the Metabolomics Innovation Centre, combining pharmacological, chemical, and target data with peer-reviewed releases through Nucleic Acids Research. The referential drug data source for PharmGKB, KEGG, PubChem, and other major databases.

go.drugbank.com →

IUPHAR/BPS Guide to Pharmacology

Joint resource of the International Union of Basic and Clinical Pharmacology and the British Pharmacological Society. Peer-reviewed overviews of drug targets, ligands, and receptor pharmacology — the authoritative target-level reference for mechanism claims.

guidetopharmacology.org →

Within the peer-reviewed literature, certain journals anchor specific domains. The Tier 1 evidence base frequently draws on journals such as:

Clinical and pharmacology

New England Journal of Medicine

The Lancet

JAMA (Journal of the American Medical Association)

BMJ (British Medical Journal)

Annals of Internal Medicine

Clinical Pharmacology & Therapeutics

British Journal of Clinical Pharmacology

Annals of Pharmacotherapy

Phytotherapy and natural products

Journal of Ethnopharmacology

Phytomedicine

Planta Medica

Phytotherapy Research

Journal of Natural Products

Fitoterapia

Nutrition

American Journal of Clinical Nutrition

Journal of Nutrition

Advances in Nutrition

British Journal of Nutrition

Regional and traditional medicine research

Chinese Medical Journal

Journal of Ayurveda and Integrative Medicine

Journal of Traditional and Complementary Medicine

Tier 1.5 — Clinical practice consensus

Where specialty-clinician consensus runs ahead of formal RCT evidence — peptide therapy, hormone optimization, specialty pharmacology — the practice literature documents the consensus position rigorously. Distinct from Tier 4: T1.5 is direct specialty-clinician consensus in fields where RCTs are structurally limited; T4 is third-party synthesis evaluating evidence with conventional clinical-evidence frameworks.

Peptide protocol literature

Specialty clinical reference texts and society consensus documents covering peptide therapy protocols where regulatory and economic barriers structurally limit RCT evidence.

Specialty-society practice guidelines

Clinical practice guidelines from specialty societies (e.g., Endocrine Society, NAMS, AACE) documenting consensus positions where practice-based knowledge precedes or substitutes for formal RCT evidence.

Specialty pharmacology consensus

Consensus documents from specialty clinical pharmacists addressing dosing, compounding, and protocol questions outside the standard pharmacopoeia.

Practice-specialty reference texts

Reference works documenting specialty practice consensus for compounds and protocols where conventional pharmacology references don't extend.

Tier 2 — Global scientific consensus bodies

Synthesis bodies that aggregate Tier 1 research into globally-coordinated positions.

WHO Expert Committees

Specifically the Expert Committee on Drug Dependence (controlled substances), the Expert Committee on the Selection and Use of Essential Medicines, the Expert Committee on Specifications for Pharmaceutical Preparations, and the Expert Committee on Biological Standardization.

who.int →

Codex Alimentarius (FAO/WHO)

The international food standards body. Codex CXS 336R-2020, for example, is the current standard for kava as a food; we cite it where relevant.

fao.org →

NIH Office of Dietary Supplements (ODS)

For supplement safety, dosing, and interaction information. NIH ODS publishes fact sheets that synthesize the peer-reviewed literature on common supplements.

ods.od.nih.gov →

WHO Traditional Medicine Strategy

The WHO framework for evaluating traditional medicine systems against scientific and quality standards. Distinct from but informing the WHO Monographs program.

who.int →

National Academy of Medicine (NAM)

Formerly the Institute of Medicine. Authoritative US synthesis body for clinical and population-health evidence; non-regulatory.

nam.edu →

Dietary Reference Intakes (Food and Nutrition Board, National Academies)

The reference standard for nutrient intake recommendations across North America. Updated by the National Academies' Food and Nutrition Board.

nationalacademies.org →

MedlinePlus (NLM)

Consumer-health synthesis from the National Library of Medicine, drawing from peer-reviewed primary sources. Useful for accessible synthesis of established findings.

medlineplus.gov →

Linus Pauling Institute Micronutrient Information Center

Academic synthesis on vitamins, minerals, and dietary phytochemicals from Oregon State University. Peer-reviewed, free public access — the most rigorous open-access micronutrient reference.

lpi.oregonstate.edu →

European Food Safety Authority (EFSA)

The EU's scientific advisory body for food and feed safety. Issues opinions on novel foods, food additives, contaminants, and nutrient/health claims.

efsa.europa.eu →

USDA FoodData Central

The USDA's authoritative food composition database, public domain. Foundation for most food-composition research globally; the food-compound equivalent of what DrugBank is for drugs.

fdc.nal.usda.gov →

Phenol-Explorer

Comprehensive polyphenol content database maintained by INRAE (France). The standard reference for polyphenol concentrations in foods — directly relevant to plant-compound claims.

phenol-explorer.eu →

EuroFIR eBASIS (Bioactive Substances in Food Information System)

The European bioactive-compound database under the European Food Information Resource consortium. Complements USDA FoodData Central with broader bioactive coverage.

eurofir.org →

USP Herbal Medicines Compendium and Dietary Supplement Verification Program

United States Pharmacopeia's standards for herbal product and dietary supplement identity, purity, strength, and quality. The pharmacopeial reference for supplement integrity.

usp.org →

Tier 3 — Specialized pharmacology references

For specific claim types where dedicated reference works are the standard:

Drug-induced nutrient depletion

Pelton’s Drug-Induced Nutrient Depletion Handbook, Cass’s Supplement Your Prescription, and the broader integrative medicine literature on medication-nutrient interactions.

Pharmacology mechanism

Goodman & Gilman as the primary reference; Katzung’s Basic & Clinical Pharmacology as secondary.

Drug interactions

Stockley’s Drug Interactions (Pharmaceutical Press), the Hansten and Horn Drug Interactions Analysis & Management reference.

Lactation safety

The NLM LactMed database (peer-reviewed, regularly updated).

ncbi.nlm.nih.gov →

Herb-drug interactions

Stockley’s Herbal Medicines Interactions (Williamson, Driver, Baxter, Pharmaceutical Press) — companion volume to Stockley’s Drug Interactions, the primary reference for herb-drug interaction claims.

Pharmacogenomics

PharmGKB (Stanford / NIH-funded Pharmacogenomics Knowledgebase) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), which publishes peer-reviewed gene-drug prescribing guidelines in Clinical Pharmacology & Therapeutics. Cited where pharmacogenomic context affects drug response.

pharmgkb.org →

Clinical reference

Merck Manual Professional Edition (MSD Manual) — broad clinical reference for differential diagnostic and therapeutic context. Freely accessible.

merckmanuals.com →

Tier 4 — Integrative medicine evidence synthesis

Bodies that aggregate peer-reviewed evidence on integrative and complementary modalities, evaluating them with conventional evidentiary standards. Distinct from traditional medicine literature in Tier 5: integrative synthesis bodies use modern clinical-evidence frameworks; traditional pharmacopoeias preserve evidence in a different epistemic register.

National Center for Complementary & Integrative Health (NCCIH, NIH)

The NIH agency funding and synthesizing research on complementary and integrative health practices. Publishes evidence summaries, fact sheets, and clinical research findings.

nccih.nih.gov →

Memorial Sloan Kettering Integrative Medicine — About Herbs

MSK's clinician-facing herb database, peer-reviewed by the institution's oncology and pharmacy services. Authoritative for herb-drug interaction concerns in oncology and clinical care contexts.

mskcc.org →

Natural Medicines Comprehensive Database

The Therapeutic Research Center's clinician-grade evidence database for natural products. Widely used by pharmacists and integrative practitioners for evidence-graded efficacy and interaction information.

naturalmedicines.therapeuticresearch.com →

European Scientific Cooperative on Phytotherapy (ESCOP) Monographs

Sixty-plus monographs harmonizing phytotherapy standards across Europe. Unlike Commission E, ESCOP monographs include explicit references — the European reference for evidence-based phytotherapy.

escop.com →

American Herbal Pharmacopoeia (AHP) Monographs and Therapeutic Compendia

Peer-reviewed by an international multi-disciplinary collective (botanists, chemists, herbalists, pharmacists, pharmacologists, physicians, toxicologists). Each monograph runs roughly thirty pages on a single botanical, integrating quality control, pharmacology, and therapeutic use.

herbal-ahp.org →

WHO Monographs on Selected Medicinal Plants

World Health Organization global synthesis of clinical and traditional evidence on plant medicines. Each monograph applies modern evidentiary frameworks — clinical pharmacology, controlled trial summaries, contraindications, adverse effects — to traditional materia medica. Distinct from the WHO TCM Monographs in Tier 5 (which focus specifically on Traditional Chinese Medicine in the traditional register).

who.int →

American Botanical Council / HerbalGram

Peer-reviewed quarterly journal and reference publisher for evidence-based herbalism. Publishers of the English translation of the German Commission E monographs.

herbalgram.org →

Herbal Medicine: Expanded Commission E Monographs

Blumenthal et al., American Botanical Council (2000) — the English translation and expansion of the German Federal Health Authority's Commission E review of 324 herbs (1978–1994). Historical foundation for Western evidence-based phytotherapy.

British Herbal Pharmacopoeia and British Herbal Compendium

British Herbal Medical Association — quality standards for 169 herbs (BHP) plus volumes of scientific information and monographs (Compendium). The British counterpart to AHP.

bhma.info →

Botanical Adulterants Prevention Program

Joint program of the American Herbal Pharmacopoeia, American Botanical Council, and the National Center for Natural Products Research at the University of Mississippi. Documents and addresses adulteration in commercial herbal products — directly relevant to "the supplement may not contain what the label says" claims.

botanicaladulterants.org →

Tier 5 — Traditional medicine literature

For compounds rooted in traditional medicine systems, we reference the relevant traditional pharmacopoeia explicitly as traditional-use evidence — distinct from RCT-grade modern research:

Ayurvedic Pharmacopoeia of India

For compounds in the Ayurvedic tradition.

WHO TCM Monographs

For compounds in Traditional Chinese Medicine.

who.int →

EMA Herbal Monographs (Traditional Use)

These explicitly distinguish “traditional use” registration from “well-established use” registration. We preserve that distinction in our analysis.

ema.europa.eu →

WHO International Standard Terminologies on Traditional Medicine

The WHO standardization framework for traditional medicine terminology, supporting consistent classification of traditional-use evidence across WHO member states.

who.int →

Pharmacopoeia of the People's Republic of China (PPRC)

The official pharmacopoeia of the PRC, including extensive monographs on Traditional Chinese Medicine materia medica with quality and identity standards.

These sources matter because dismissing them would mean ignoring documented evidence on compounds humans have used for centuries. Including them honestly means flagging them as the type of evidence they are — distinct from RCT-grade modern research, distinct again from integrative-medicine synthesis (Tier 4), preserved as their own knowledge tradition.

Tier 6 — National regulators (legal context)

National regulators close the source hierarchy because their authority is legal, not scientific. We cite them for what they are authoritative on: legal status, approved indications, formal warnings, and prescribing information for specific markets. When the regulatory position aligns with the current science, we say so. When it diverges, we name the divergence and present the science.

FDA prescribing information

For what's approved, what's contraindicated, and what's specifically warned against in US-marketed prescription drugs.

fda.gov →

EMA (European Medicines Agency)

For European market approvals, herbal monographs, and post-market safety actions.

ema.europa.eu →

DEA scheduling

For US controlled substance status, framed clearly as legal status (not as scientific assessment of risk).

dea.gov →

Other national regulators

MHRA (United Kingdom Medicines and Healthcare products Regulatory Agency), TGA (Australia Therapeutic Goods Administration), Health Canada (including the Drug Product Database and Natural Health Products Database), PMDA (Japan Pharmaceuticals and Medical Devices Agency), and Swissmedic. Cited where users' regional context calls for them.

DailyMed (NLM)

Structured FDA-derived drug labeling, maintained by the National Library of Medicine. Primary US source for current prescribing information in machine-readable form.

dailymed.nlm.nih.gov →

FDA Adverse Event Reporting System (FAERS)

FDA's pharmacovigilance database for post-market adverse event reports. Cited for known safety signals where applicable.

fda.gov →

FDA pharmacogenomic biomarkers list

The FDA's regulatory list of pharmacogenomic biomarkers in approved drug labeling. Complements PharmGKB / CPIC (Tier 3) by reflecting where pharmacogenomic information has reached US regulatory recognition.

fda.gov →

We frame these citations as what they are: regulatory positions, not scientific consensus. When the regulatory position aligns with current science, we say so. When it diverges, we explain the divergence and present the science.

Tier 0 — Preliminary (in vitro / animal)

Preliminary findings from in vitro studies or animal-only data — pre-clinical evidence not yet validated in humans. When a claim rests only on this, the analyzer flags it explicitly, so you can weigh it as the early-stage signal it is.

None — Insufficient peer-reviewed evidence

No peer-reviewed evidence base supports the claim. The analyzer says so plainly rather than manufacturing a plausible answer, and defers to your healthcare provider. T0 and None close the scale so that every tier a finding can carry is accounted for here.

03.

What the corpus actually contains

The tier hierarchy above isn’t a list of sources the analyzer looks up at runtime. It’s the editorial universe of evidence Regimens is built to reason within — the texts, databases, references, and clinical materials that informed the analyzer’s training and that anchor the curated framing for specific compounds. When the corpus expands, the framing expands; the analyzer doesn’t gain new runtime reach, it gains better-grounded priors and more curated overrides. The curated citations behind specific compounds are published below in “Cited evidence, by compound” — the actual references, with their evidence tiers and direct links.

04.

How we read the sources

Here is the honest mechanical truth about how Regimens produces its analyses, because the editorial discipline depends on you understanding it.

Regimens uses Anthropic’s Claude as its analytical engine. Claude does not look up documents at runtime. It generates its responses from statistical patterns absorbed during training — a training corpus that included peer-reviewed pharmacology literature, regulatory advisories, structured clinical references, and the other source types named in the tier hierarchy above. So when Claude produces a claim about a drug interaction, that claim is genuinely informed by those sources. But it is not extracted from any one of them.

This matters because it shapes what “source fidelity” honestly means here. If we asked Claude to attach a specific paper to each individual claim, it would generate a plausible-sounding attribution that it did not actually consult — citation theater that looks rigorous but introduces fabrication into the very layer that’s supposed to defend against it. So we don’t do that.

What we do instead is the discipline this whole page describes:

We don’t fill gaps with plausibility. When the curated source hierarchy doesn’t support a claim, the analyzer is instructed to label the evidence as insufficient — not to generate a plausible-sounding answer to fill the silence.

We don’t smooth disagreement. When peer-reviewed pharmacology and a regulator’s position diverge, when traditional use and modern evidence disagree, when two clinical studies contradict each other — the analyzer is instructed to name the divergence, not paper over it.

We use the tier signal as the load-bearing source-fidelity output. Every finding in your report carries a tier label honestly indicating the strength of evidence behind it. T1 means peer-reviewed pharmacology and clinical research supports the claim. T6 means it’s grounded only in regulatory framing, not science. NONE means the corpus doesn’t support the claim at all and we’re saying so.

We curate context overrides for the compounds where general training is known to be weak. Where the analyzer would otherwise reason from stale or contested training data, Regimens injects curator-authored framing directly into the prompt so the analysis reasons from the curated framing instead.

This is what source-fidelity actually looks like at the layer Regimens operates. The tier hierarchy above is the universe of evidence the analyzer is built to reason within. The per-finding tier label tells you how strongly that universe supports each specific claim. That’s the honest commitment, and it’s what we’re building everything else on.

05.

What we don’t do

We don't pretend our analysis is medical advice.

It isn't. Always consult your doctor and healthcare team before making changes to your regimen.

We don't claim diagnostic capability.

Regimens identifies documented interactions and patterns; it doesn't diagnose conditions or replace clinical evaluation.

We don't have access to your medical records.

Our analysis is based on the regimen you log, the personal health profile you share with us, and our source corpus. We can't account for medical history we don't know about.

We don't run live searches.

Regimens AI uses a frozen knowledge corpus, plus structured prompts that prioritize the source hierarchy above. New research published after the model's training date won't be reflected — and we say that directly when it might matter.

We're not HIPAA-covered.

Regimens is a working tool for personal pharmacology, explicitly not a clinical service or HIPAA-covered application. Our privacy policy explains how we handle the data you share with us.

06.

How we work against AI’s failure modes

Our analysis is generated by Regimens AI, configured with the source hierarchy described above. Like all AI systems, it can occasionally generate plausible-sounding but inaccurate information.

Generative AI fabricates plausible-sounding sources when asked to attach specific citations to individual claims. Regimens doesn’t pretend otherwise. The defenses described on this page are designed to honor what the underlying mechanism actually does — and to refuse the kinds of attribution it can’t honestly produce. The four disciplines this page describes — a curated source corpus, a per-finding evidence-tier signal (T1, T1.5, T2, T3, T4, T5, T6, T0, NONE), curated context overrides for compounds where training data is thin or stale, and explicit gap-flagging — are what source fidelity actually looks like at this layer.

We don’t claim our analysis is perfect. We claim it’s better-grounded and more honestly framed than any wellness AI tool we know of, and we welcome corrections from clinicians, researchers, and informed users.

07.

Questions or corrections?

If you believe a claim is misframed against the evidence, or a source in our corpus is wrong, we want to know. Email support@regimens.app with specifics. We’ll investigate and update.

08.

Cited evidence, by compound

The sources below back the compound information in Regimens. Each is a curator-verified reference at a stated evidence tier; where a DOI or PubMed ID is available it links directly to the source.

7-OH

  • T0 · Preliminary (in vitro / animal)Todd 2020, Sci Rep 10:19158 (doi 10.1038/s41598-020-76119-w) — 7-OH at the human µ-opioid receptor, in vitro
  • T6 · FDA AdvisoryFDA 2025, "7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat" (fda.gov; NPDS data through Apr 2025)
  • T6 · FDA AdvisoryFDA warning letters to 7 firms marketing 7-OH products, dated June 25, 2025 (announced July 15, 2025; representative: Hydroxie LLC, MARCS-CMS 709661) — tablets, gummies, drink mixes, shots
  • T6 · FDA AdvisoryFDA recommendation to HHS/DEA for CSA scheduling of 7-OH, July 29, 2025 (HHS release) + FDA/DOJ seizure action, Dec 2, 2025 (~73,000 units, ~$1M, three Missouri firms)
  • T6 · DEA ScheduleDEA notices of intent: 91 FR 40917 (Jul 6, 2026, Docket DEA-1570) and revised notices Oct 14, 2026 (FR Docs 2026-20943 / 2026-20942) — temporary Schedule I placement of 7-OH above threshold
  • T6 · DEA ScheduleDEA temporary scheduling ORDER, 91 FR 54948 (Aug 26, 2026, Docket DEA-1644) — mitragynine pseudoindoxyl (MP), MGM-15, MGM-16 placed in Schedule I
  • T6 · FDA AdvisoryFDA, "FDA and Kratom" (fda.gov, current 12/02/2025) — the 7-OH passage

Adderall (amphetamine/dextroamphetamine)

  • T1 · Cochrane ReviewCastells X et al. 2018, Cochrane Database Syst Rev 8:CD007813 (PMID 30091808) — 19 placebo-controlled RCTs, 2,521 adults; mean study length 5.3 weeks. Clinician-rated symptom severity: all amphetamines SMD −0.90 (95% CI −1.04 to −0.75); mixed amphetamine salts SMD −0.80 (−0.93 to −0.66; 5 studies, 1,083 participants). Withdrawal for adverse events RR 2.69 (1.63 to 4.45). Retention not improved (RR 1.06; 0.99 to 1.13). Evidence rated low or very low quality; 16 of 19 studies industry funded.
  • T1 · PubMedCortese S et al. 2018, Lancet Psychiatry 5(9):727-738 (PMID 30097390) — network meta-analysis of 133 double-blind RCTs; 12-week efficacy analysis in 10,068 children and adolescents and 8,131 adults. Clinician-rated ADHD symptoms vs placebo: amphetamines SMD −1.02 (95% CI −1.19 to −0.85) in children and adolescents, −0.79 (−0.99 to −0.58) in adults. Dropout for side effects vs placebo: OR 2.30 (1.36 to 3.89) and 3.26 (1.54 to 6.92). Insufficient data at 26 and 52 weeks.
  • T1 · Cochrane ReviewPunja S et al. 2016, Cochrane Database Syst Rev 2:CD009996 (PMID 26844979) — 23 RCTs, 2,675 children and adolescents aged 3 to 17; most trials under 6 months. ADHD core symptoms improved on parent ratings (SMD −0.57; 95% CI −0.86 to −0.27), teacher ratings (−0.55; −0.83 to −0.27) and clinician ratings (−0.84; −1.32 to −0.36). Decreased appetite RR 6.31 (2.58 to 15.46); insomnia RR 3.80 (2.12 to 6.83); abdominal pain RR 1.44 (1.03 to 2.00). Quality of evidence low to very low.
  • T1 · PubMedLi L et al. 2024, JAMA 331(10):850-860 (PMID 38470385) — Swedish national registers, 148,578 people diagnosed with ADHD (median age at diagnosis 17.4 years). Starting ADHD medication vs not starting: 2-year all-cause mortality 39.1 vs 48.1 per 10,000 (HR 0.79; 95% CI 0.70 to 0.88); unnatural-cause mortality HR 0.75 (0.66 to 0.86); natural-cause mortality HR 0.86 (0.71 to 1.05), not significant.
  • T1 · PubMedIlieva IP et al. 2015, J Cogn Neurosci 27(6):1069-1089 (PMID 25591060) — meta-analysis, 48 studies, 1,409 healthy participants, methylphenidate and amphetamine: small but significant effects on inhibitory control and short-term episodic memory; small effects on working memory, significant in one of two analyses; medium effects on delayed episodic memory, qualified by evidence of publication bias. Authors: the effect on healthy cognition "is probably modest overall".
  • T1 · PubMedFarhat LC et al. 2025, Lancet Psychiatry 12(5):355-365 (PMID 40203844) — network meta-analysis of 102 short-term RCTs (median 7 weeks): 13,315 children and adolescents, 9,387 adults. Amphetamines vs placebo: systolic blood pressure +2.3 mmHg in adults (95% CI 0.66 to 3.94; very low confidence); diastolic +1.93 mmHg in children and adolescents (0.74 to 3.11; high confidence). Stimulants were not associated with larger increases than atomoxetine or viloxazine.
  • T1 · PubMedZhang L et al. 2024, JAMA Psychiatry 81(2):178-187 (PMID 37991787) — Swedish nested case-control study in 278,027 people with ADHD aged 6 to 64 (10,388 cardiovascular cases, 51,672 controls). Cumulative ADHD medication use vs nonuse: 1 to 2 years AOR 1.09 (95% CI 1.01 to 1.18); 3 to 5 years 1.27 (1.17 to 1.39); over 5 years 1.23 (1.12 to 1.36). Per year of use: AOR 1.04 (1.03 to 1.05). Hypertension at 3 to 5 years: 1.72 (1.51 to 1.97). Arterial disease at 3 to 5 years: 1.65 (1.11 to 2.45).
  • T1 · PubMedZhang L et al. 2022, JAMA Netw Open 5(11):e2243597 (PMID 36416824) — meta-analysis, 19 studies, 3,931,532 participants: ADHD medication and any cardiovascular disease, stimulants RR 1.24 (95% CI 0.84 to 1.83); cardiac arrest or arrhythmias RR 1.60 (0.94 to 2.72); neither significant. Habel LA et al. 2011, JAMA 306(24):2673-2683 (PMID 22161946) — young and middle-aged adults: serious cardiovascular events, current use vs nonuse RR 0.83 (0.72 to 0.96); current vs remote use 1.03 (0.86 to 1.24).
  • T1 · PubMedMoran LV et al. 2019, N Engl J Med 380(12):1128-1138 (PMID 30893533) — 221,846 matched young people with ADHD starting a stimulant: new psychosis in 0.21% on amphetamine vs 0.10% on methylphenidate (HR 1.65; 95% CI 1.31 to 2.09). Moran LV et al. 2024, Am J Psychiatry 181(10):901-909 (PMID 39262211) — 1,374 cases, 2,748 controls: past-month amphetamine, psychosis or mania aOR 2.68 (1.90 to 3.77); above 30 mg dextroamphetamine equivalents, 5.28-fold; methylphenidate aOR 0.91 (0.54 to 1.55).
  • T1 · PubMedKidwell KM et al. 2015, Pediatrics 136(6):1144-1153 (PMID 26598454) — meta-analysis, 9 studies, 246 youth with ADHD: stimulants lengthened sleep latency (effect size 0.54), lowered sleep efficiency (−0.32) and shortened total sleep time (−0.59). Weiss MD et al. 2006, J Am Acad Child Adolesc Psychiatry 45(5):512-519 (PMID 16670647) — stimulant-treated children with ADHD and initial insomnia: melatonin cut time to fall asleep by 16 minutes vs placebo; no effect on ADHD symptoms.
  • T1 · PubMedSwanson JM et al. 2017, J Child Psychol Psychiatry 58(6):663-678 (PMID 28295312) — MTA follow-up into adulthood: participants with consistent or inconsistent long-term medication use were 2.55 ± 0.73 cm shorter as adults than those with negligible use; consistent vs inconsistent use, 2.36 ± 1.13 cm shorter. Faraone SV et al. 2008, J Am Acad Child Adolesc Psychiatry 47(9):994-1009 (PMID 18580502) — review: stimulants modestly reduced expected height and weight; deficits attenuated over time.
  • T1 · PubMedHumphreys KL et al. 2013, JAMA Psychiatry 70(7):740-749 (PMID 23754458) — meta-analysis of longitudinal studies (3 to 11 studies per outcome) comparing children with ADHD who were and were not treated with stimulant medication: comparable later outcomes for any substance use and for abuse or dependence, across all substance types. Conclusion: stimulant treatment "neither protects nor increases the risk of later substance use disorders". NIH funded.
  • T1 · PubMedHuybrechts KF et al. 2018, JAMA Psychiatry 75(2):167-175 (PMID 29238795) — US cohort of 1,813,894 pregnancies. Congenital malformations per 1,000 infants: 35.0 unexposed, 45.4 with amphetamines, 45.9 with methylphenidate. Adjusted relative risk with amphetamines: any malformation 1.05 (95% CI 0.93 to 1.19); cardiac malformations 0.96 (0.78 to 1.19). Methylphenidate, cardiac malformations, pooled with Nordic data: RR 1.28 (1.00 to 1.64). NIH funded.
  • T1 · PubMedHaffey MB et al. 2009, Postgrad Med 121(5):11-19 (PMID 19820270) — 24 healthy adults randomized (21 completed): omeprazole given with extended-release mixed amphetamine salts (MAS XR) or with lisdexamfetamine. MAS XR total exposure unchanged (AUC 640.8 vs 643.9 ng·h/mL; Cmax 36.6 vs 38.1 ng/mL), but median time to peak fell from 5 to 2.75 hours; 57.1% to 61.9% of subjects had a peak at least 1 hour earlier. No clear trend with lisdexamfetamine.
  • T1 · PubMedTanna RS et al. 2023, Clin Pharmacol Ther 113(6):1315-1325 (PMID 36924284) — 12 healthy adults, single low dose of kratom tea (2 g). CYP2D6 probe dextromethorphan: AUC ratio 0.99 (90% CI 0.83 to 1.19), Cmax 0.96 (0.78 to 1.19): no effect. CYP3A probe midazolam: AUC 1.39 (1.23 to 1.57), Cmax 1.50 (1.32 to 1.70), a modest increase attributed mainly to intestinal CYP3A. NIH (NCCIH) funded.
  • T1 · PubMedArnold LE et al. 2011, J Child Adolesc Psychopharmacol 21(1):1-19 (PMID 21309695) — placebo-controlled double-blind pilot trial of zinc alone and combined with amphetamine. The optimal amphetamine dose (mg/kg) with zinc 15 mg twice daily was 37% lower than with placebo; not with 15 mg once daily. Other clinical outcomes were equivocal. Zinc up to 30 mg/day was safe for at least 8 weeks; copper and iron blood indices were not impaired. NIH funded.
  • T1.5 · PubMedWolraich ML et al. 2019, Pediatrics 144(4):e20192528 (PMID 31570648) — American Academy of Pediatrics guideline. Age 6 to 12: "the PCC should prescribe FDA-approved medications for ADHD, along with PTBM and/or behavioral classroom intervention" (Grade A). Age 12 to 18: FDA-approved medications "with the adolescent's assent" (Grade A). Age 4 to 6: behavioral treatment first; methylphenidate may be considered. Titrate doses "to achieve maximum benefit with tolerable side effects" (Grade B).
  • T3 · PubMedIbrahim K et al. 2015, J Atten Disord 19(7):551-568 (PMID 25253684) — literature review of drug holidays from ADHD medication over four decades: practiced by 25% to 70% of families, more often in school holidays, to test whether medication is still needed and to manage side effects and tolerance. "There was evidence of a positive impact on child growth with longer breaks from medication, and shorter breaks could reduce insomnia and improve appetite."
  • T6 · FDA PrescribingAdderall tablets, FDA prescribing information (Teva; DailyMed set f22635fe, effective 2024-05-29), Boxed Warning: "Adderall has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction." Misuse and abuse "can result in overdose and death", a risk "increased with higher doses or unapproved methods of administration, such as snorting or injection". Schedule II; may produce physical dependence and tolerance.
  • T6 · FDA PrescribingAdderall tablets, FDA prescribing information (Teva; DailyMed set f22635fe, effective 2024-05-29). Contraindicated in patients taking MAOIs "or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis". Serotonin syndrome may occur with MAOIs, SSRIs, SNRIs, triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's Wort. CYP2D6 inhibitors "may increase the exposure".
  • T6 · FDA PrescribingAdderall tablets, FDA prescribing information (Teva; DailyMed set f22635fe, effective 2024-05-29), Warnings: "CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm)." Avoid in serious cardiac disease. Psychotic or manic symptoms: about 0.1% of stimulant-treated patients vs 0% on placebo in pooled short-term trials. Also: seizures, peripheral vasculopathy including Raynaud's phenomenon, tics.
  • T6 · FDA PrescribingAdderall and Adderall XR, FDA prescribing information (DailyMed sets f22635fe and aff45863): amphetamines are thought to block reuptake and increase release of norepinephrine and dopamine; "The mode of therapeutic action in ADHD is not known." CYP2D6 is involved in metabolism. Urinary recovery of unchanged amphetamine ranges "from 1 to 75%, depending on urinary pH". Alkalinizing agents (GI antacids and urinary) increase blood levels; acidifying agents (e.g., ascorbic acid) decrease them.
  • T6 · FDA PrescribingAdderall and Adderall XR, FDA prescribing information (DailyMed sets f22635fe and aff45863): peak levels about 3 hours after a tablet and about 7 hours after an XR capsule; half-life in adults 10 h (d-) and 13 h (l-amphetamine). Tablets: first dose on awakening, further doses at 4 to 6 hour intervals; "Late evening doses should be avoided because of the resulting insomnia." XR: once daily upon awakening; a high-fat meal delays peak by about 2.5 hours without changing the amount absorbed.
  • T6 · FDA PrescribingAdderall XR, FDA prescribing information (Takeda; DailyMed set aff45863, effective 2026-04-30), 4-week adult trial, drug (n=191) vs placebo (n=64): dry mouth 35% vs 5%; loss of appetite 33% vs 3%; insomnia 27% vs 13%; headache 26% vs 13%; weight loss 10% vs 0%; tachycardia 6% vs 3%; stopped for adverse events 12.0% vs 1.6%. Pediatric: not recommended under 6 years (higher exposure and more weight loss); adolescents lost 1.1 and 2.8 lb in 4 weeks on 10 and 20 mg.
  • T6 · FDA Prescribingdderall XR, FDA prescribing information (Takeda; DailyMed set aff45863, effective 2026-04-30), 7.2 Interference with Laboratory Tests: "Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations." Adderall XR can interfere with ioflupane I-123 dopamine transporter (DAT) imaging, which "may lead to false-positive diagnostic results"; allow an adequate washout period.
  • T6 · FDA PrescribingAdderall XR, FDA prescribing information (Takeda; DailyMed set aff45863, effective 2026-04-30), 8.1 and 8.2: published studies and postmarketing reports "have not identified a drug-associated risk of major birth defects and miscarriage"; infants born to mothers taking amphetamines "have an increased risk of premature delivery and low birth weight"; monitor for withdrawal symptoms. Amphetamine is present in human milk at relative infant doses of 2 to 13.8%; "breastfeeding is not recommended".
  • T6 · FDA AdvisoryFDA Drug Safety Communication, 05-11-2023, "FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions" (fda.gov/drugs/drug-safety-communications): "We are requiring the Boxed Warning, FDA's most prominent warning, to be updated". Nonmedical use: most common source is friends or family (56 to 80%); past-year nonmedical use 4.1 to 7.5% among adults aged 18 to 25. "Never provide any of your prescription stimulant medicine to anyone else".
  • T6 · DEA ScheduleDEA Drug Scheduling (dea.gov/drug-information/drug-scheduling): Schedule II drugs have "a high potential for abuse, with use potentially leading to severe psychological or physical dependence." Adderall is named among the Schedule II examples, with Dexedrine, Ritalin, methamphetamine, oxycodone and fentanyl. The Adderall tablet label states: "Adderall contains amphetamine, a Schedule II controlled substance."

Apixaban

  • T3 · PubMedSt John's Wort as a strong CYP3A4/P-gp inducer — class evidence (Huppertz 2018 rivaroxaban AUC −26%; Jiang 2004 warfarin effect −21%); apixaban-specific magnitude label-qualitative (Eliquis §7.2 names SJW to avoid)
  • T6 · FDA PrescribingFDA apixaban (Eliquis) prescribing label §12.3 / §2 (food) + §7.1–7.2 (CYP3A4/P-gp)

AshwagandhaWithania somnifera

  • T1 · PubMedSharma AK, Basu I, Singh S. 2018, J Altern Complement Med 24(3):243-248 (PMID 28829155) — 600 mg/day root extract x 8 wk in subclinical hypothyroidism, n=50: serum T3 +41.5%, T4 +19.6% (both p<0.0001 at wk 8); TSH significantly reduced vs placebo (p=0.0002).
  • T1 · PubMedChandrasekhar K, Kapoor J, Anishetty S. 2012, Indian J Psychol Med 34(3):255-262 (PMC3573577) — KSM-66 600 mg/day (300 mg BID) x 60 d, n=64: serum cortisol -27.9% vs -7.9% placebo (p=0.002); Perceived Stress Scale -44% vs -5.5% (p<0.0001); no serious adverse events.
  • T1 · PubMedAkhgarjand C et al. 2022, Phytother Res 36(11):4115-4124 (PMID 36017529) — meta-analysis, 12 RCTs, n=1002 (dose 240-1000 mg/d, 8-12 wk): anxiety SMD 1.55 (95% CI 0.74-2.37, p=.005, I²=93.8%); stress SMD 1.75 (95% CI 1.22-2.29, p=.005, I²=83.1%). GRADE certainty LOW for both.
  • T1 · PubMedLopresti AL, Drummond PD, Smith SJ. 2019, Am J Mens Health 13(2):1557988319835985 (PMC6438434, PMID 30854916) — crossover RCT, aging overweight men, Shoden 600 mg/day x 8 wk: testosterone +14.7% (p=.010), DHEA-S +18% (p=.005); cortisol and estradiol non-significant.
  • T3 · PubMedBjornsson HK et al. 2020, Liver Int 40(4):825-829 (PMC8041491) — DILIN + Iceland case series, n=5: latency 2-12 wk, cholestatic/mixed pattern, jaundice in all, pruritus, peak bilirubin 5.9-14.4 mg/dL, ALT 261-580 U/L; no hepatic failure, resolved 1-9 mo; chemical analysis confirmed ashwagandha (not contamination).
  • T4 · NCCIHNCCIH, "Ashwagandha: What the Science Says" (nccih.nih.gov/health/ashwagandha, dated 2023) — may help short-term stress/insomnia; anxiety evidence unclear; insufficient evidence for cognition, athletic performance, diabetes, menopause. Safe only short-term (<=3 mo). AVOID in pregnancy & breastfeeding; not recommended in autoimmune or thyroid disorders or before surgery. Possible interactions: diabetes meds, blood-pressure meds, immunosuppressants, sedatives, anticonvulsants, thyroid-hormone meds

Atorvastatin

  • T1 · PubMedBailey 2013, CMAJ 185:309 (PMID 23184849) — grapefruit mechanism + dose-dependence
  • T6 · FDA PrescribingFDA atorvastatin (Lipitor) prescribing label §5.1 / §7.1 / §12.3 / Table 2 / Table 5

BananaMusa acuminata

  • T0 · Preliminary (in vitro / animal)Wohlt D et al. 2021, Foods 10(5):1022 (PMID 34066737) — banana peel polyphenol oxidase: thermal inactivation of 'Prata' and 'Cavendish' PPO was achieved at 90 °C after 5 and 15 min; overall high thermal stability, attributed mainly to membrane-bound PPO. Escobedo-Avellaneda Z et al. 2017, Food Sci Technol Int 23(2):185-193 (PMID 27831529) — orange-strawberry-banana beverage: thermal processing at 80 °C for 7 min inactivated 99.6% of PPO; 600 MPa at 64 °C for 10 min inactivated 96.2%.
  • T1 · PubMedOttaviani JI et al. 2023, Food Funct 14(18):8217-8228 (PMID 37615673; NCT03526094) — controlled, single-blinded crossover in healthy men. Cocoa extract flavan-3-ols taken as a capsule (541 mg), a mixed berry smoothie (484 mg) or a banana smoothie (638 mg; 177 g ripe frozen banana + almond milk), drunk within 1 h of blending. Peak plasma metabolites: 680 ± 78 (capsule), 659 ± 104 (berry), 96 ± 47 nmol/L (banana). Banana Cmax 84 ± 9% and AUC 81 ± 11% lower than capsule. Funded by Mars, Inc.
  • T2 · NIH ODSNIH ODS Potassium Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/Potassium-HealthProfessional; updated June 2, 2022), Table 2: "Banana, 1 medium" 422 mg potassium, 9% of the 4,700 mg Daily Value (USDA FoodData Central values). Adequate Intake, adults 19+: 3,400 mg/day men, 2,600 mg/day women. "In healthy people with normal kidney function, high dietary potassium intakes do not pose a health risk because the kidneys eliminate excess amounts in the urine."
  • T3 · PubMedBlanco C et al. 1994, Ann Allergy 73(4):309-14 (PMID 7943998) — prospective clinic study of 25 patients with latex allergy (23 women; 9 greenhouse and 6 hospital workers). 13 patients (52%) had 42 food allergies, 23 of them systemic anaphylaxis. Most frequent: avocado (9), chestnut (9), banana (7), kiwi (5), papaya (3). RAST inhibition demonstrated cross-reactivity among latex, avocado, chestnut and banana. Authors proposed a "latex-fruit syndrome".
  • T3 · PubMedFeldman JM, Lee EM 1985, Am J Clin Nutr 42(4):639-43 (PMID 2413754) — radioenzymatic assay of serotonin in 80 foods. High-serotonin fruits (mean ± SEM, µg/g): plantain 30.3 ± 7.5; pineapple 17.0 ± 5.1; banana 15.0 ± 2.4; kiwi 5.8 ± 0.9; plums 4.7 ± 0.8; tomatoes 3.2 ± 0.6. Eating these fruits and nuts increased urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion with no change in platelet serotonin. Authors: these foods should not be eaten while a urine is being collected for 5-HIAA analysis.
  • T3 · PubMedWalker SE, Shulman KI, Tailor SA, Gardner D 1996, J Clin Psychopharmacol 16(5):383-8 (PMID 8889911) — liquid chromatography of tyramine in 51 food samples that still appear on MAOI restricted-food lists, including bananas and banana peels. Dangerously high (≥6 mg per serving): chicken liver aged 9 days, air-dried sausage, soy sauce and sauerkraut. Authors: only foods with high tyramine per serving should remain absolutely restricted; all other foods analyzed are safe or safe in moderation.

Berberine

  • T0 · PubMedChan E. 1993, Biol Neonate 63(4):201-208 (PMID 8513024) — in vitro + rat. Berberine displaced bilirubin from albumin ~10x more potently than phenylbutazone and ~100x more than papaverine (molar basis, peroxidase method). In rats, IP berberine 10-20 ug/g/d x 1 wk significantly lowered serum bilirubin protein binding and raised unbound + total bilirubin. Conclusion: best avoided in jaundiced neonates and pregnant women.
  • T1 · PubMedDong H, Wang N, Zhao L, Lu F. 2012, Evid Based Complement Alternat Med 2012:591654 (PMC3478874, PMID 23118793) — meta-analysis, 14 RCTs, n=1068: HbA1c -0.72% vs lifestyle (p<0.00001); fasting glucose -0.87 mmol/L; TC -0.58, LDL -0.58, TG -0.48 mmol/L. Glucose-lowering comparable to (not superior to) oral hypoglycemics; additive when combined.
  • T1 · PubMedWu X, Li Q, Xin H, Yu A, Zhong M. 2005, Eur J Clin Pharmacol 61(8):567-572 (PMID 16133554) — renal-transplant recipients, berberine 0.2 g TID. Clinical arm (n=52 vs 52): ciclosporin A trough and conc/dose ratio 29.3%/27.8% HIGHER than berberine-free controls (p<0.05). PK sub-study (n=6, 12 d berberine): CsA AUC +34.5%, Css +34.5%, Cmin +88.3%, t1/2 +2.7 h, CL/F -40.4% (p<0.05). No liver/renal harm.
  • T1 · PubMedGuo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. 2012, Eur J Clin Pharmacol 68(2):213-217 (PMID 21870106) — healthy subjects, berberine 300 mg TID x 2 wk, probe cocktail: CYP2D6 (dextromethorphan) urinary ratio ↑ ~9-fold; CYP2C9 (losartan/E-3174 ratio) doubled; CYP3A4 (midazolam) Cmax +38%, AUC0-inf +40%, oral CL -27%; CYP2C19 (omeprazole) and CYP1A2 (caffeine) unchanged.

BlueberriesVaccinium corymbosum

  • T1 · PubMedHe Y et al. 2026, Nutr Res 149:162-177 (PMID 41974068) — systematic review and meta-analysis, 14 randomized controlled trials, 632 healthy participants. Flow-mediated dilation improved by 1.11% (95% CI 0.50 to 1.72; I²=23%). No significant change in systolic blood pressure (−0.11 mmHg; −2.82 to 2.60), diastolic blood pressure (−0.46 mmHg; −2.80 to 1.87), executive function (SMD 0.21; −0.05 to 0.46) or mood (MD 1.67; −1.35 to 4.69).
  • T1 · PubMedCurtis PJ et al. 2019, Am J Clin Nutr 109(6):1535-1545 (PMID 31136659; NCT02035592; corrigendum PMID 31667509) — 6-month double-blind RCT, 115 adults with metabolic syndrome: freeze-dried blueberry equal to 1 cup/day (150 g; 364 mg anthocyanins), ½ cup/day, or placebo. Primary endpoint, insulin resistance: unchanged. 1 cup/day: flow-mediated dilation +1.45% (95% CI 0.83 to 2.1), augmentation index −2.24%; HDL cholesterol +0.08 mmol/L in statin non-users. ½ cup/day: no effect on any biomarker.
  • T1 · PubMedWood E et al. 2023, Am J Clin Nutr 117(6):1306-1319 (PMID 36972800; NCT04084457; corrigendum PMID 40782825) — 12-week double-blind RCT, 61 healthy adults aged 65-80: 26 g/day freeze-dried wild blueberry powder (302 mg anthocyanins; equal to 178 g fresh) vs placebo. Flow-mediated dilation +0.86% (95% CI 0.56 to 1.17); 24-h ambulatory systolic blood pressure −3.59 mmHg (−6.95 to −0.23). Immediate word recall and task-switch accuracy improved. No change in cerebral blood flow or gut microbiota.
  • T1 · PubMedZhu Y et al. 2017, J Hum Hypertens 31(3):165-171 (PMID 27654329) — meta-analysis, 6 RCTs, 204 participants: systolic −0.28 mmHg (95% CI −1.11 to 0.56; I²=87%), diastolic −0.5 mmHg (−1.24 to 0.24; I²=84%); no significant effect. Delpino FM et al. 2024, Phytother Res 38(2):646-661 (PMID 37963472) — 17 RCTs of blueberry and/or cranberry in cardiometabolic disease: systolic −0.81 mmHg (−2.26 to 0.63), diastolic −0.15 mmHg (−1.36 to 1.05); "neutral effects on SBP and DBP".
  • T1 · PubMedda Silva ABN et al. 2025, Biogerontology 26(5):171 (PMID 40856863) — meta-analysis, 9 RCTs, 513 older adults with mild cognitive impairment or subjective decline: episodic memory improved (SMD 0.34; 95% CI 0.11 to 0.57); four other domains not improved. Soveid N et al. 2023, CNS Neurol Disord Drug Targets 22(7):1090-1101 (PMID 35676847) — 14 trials, 6 pooled: no effect on mood, attention or one-back accuracy; two-back accuracy improved (WMD 0.08; 0.02 to 0.13).
  • T1 · PubMedMiller MG et al. 2018, Eur J Nutr 57(3):1169-1180 (PMID 28283823) — RCT, 37 adults aged 60-75, 24 g/day freeze-dried blueberry (= 1 cup) × 90 days: fewer repetition errors, lower task-switch cost; gait and balance unchanged. Whyte AR et al. 2016, Eur J Nutr 55(6):2151-2162 (PMID 26437830) — crossover, 21 children aged 7-10, 15 or 30 g wild blueberry powder, single doses. Krikorian R et al. 2010, J Agric Food Chem 58(7):3996-4000 (PMID 20047325) — 9 older adults, wild blueberry juice, 12 weeks.
  • T1 · PubMedDelpino FM et al. 2022, Nutr Metab Cardiovasc Dis 32(5):1093-1109 (PMID 35282984) — 22 RCTs of blueberry or cranberry; with diabetes: fasting glucose −17.72 mg/dL (95% CI −29.62 to −5.82), HbA1c −0.32% (−0.57 to −0.07); insulin resistance null; general population not significant. Azari H et al. 2022, Food Funct 13(9):4875-4900 (PMID 35445669) — 21 blueberry studies pooled: glucose, HbA1c and HOMA-IR not significant. Stull AJ et al. 2010, J Nutr 140(10):1764-1768 (PMID 20724487) — RCT, 32 adults.
  • T1 · PubMedCarvalho MF et al. 2021, Nutr Res 91:67-80 (PMID 34139510) — 18 RCTs reviewed, 12 pooled: blueberry lowered total cholesterol, LDL cholesterol and diastolic blood pressure; no significant difference in glycemic markers or anthropometric measures. Miraghajani M et al. 2020, Complement Ther Med 53:102389 (PMID 33066847) — 11 studies: triglycerides −0.27 mmol/L, not significant (P=0.06); "Current evidence is insufficient to show a benefit of blueberry supplements in modifying CVD risk factors".
  • T1 · PubMedHodges JK et al. 2023, Am J Clin Nutr 118(2):382-390 (PMID 37269909; NCT02630797) — randomized crossover, 14 healthy postmenopausal women with 41Ca-labeled bone: freeze-dried blueberry powder 17.5, 35 or 70 g/day (0.75, 1.5 or 3 cups fresh) for 6 weeks each. Net bone calcium retention vs no treatment: +6% at the low dose (95% CI 2.50 to 8.60), +4% at the medium dose (0.96 to 7.90); no benefit at the high dose. Urinary hippuric acid rose dose-dependently. NIH funded.
  • T1 · PubMedKalt W et al. 2014, J Agric Food Chem 62(46):11180-11189 (PMID 25335781) — two placebo-controlled crossover trials of blueberry anthocyanins: S2 (n=72; 3 weeks; 271 and 7.11 mg cyanidin 3-glucoside equivalents) and L1 (n=59; 12 weeks; 346 mg). "In both S2 and L1 neither dark adaptation nor night vision was improved by anthocyanin intake." Recovery of visual acuity after photobleaching was faster (S2 P=0.014; L1 P=0.027 at 8 weeks, P=0.030 at 12 weeks).
  • T1 · PubMedMcLeay Y et al. 2012, J Int Soc Sports Nutr 9(1):19 (PMID 22564864; PMC3583121) — randomized crossover, 10 women: a blueberry smoothie or a placebo of similar antioxidant capacity 5 and 10 h before, then immediately, 12 and 36 h after 300 strenuous eccentric quadriceps contractions. Over 60 h, peak isometric tension recovered faster with blueberry (interaction P=0.047); "a similar trend" for concentric and eccentric strength. Inflammation biomarkers were still elevated at 60 h.
  • T1 · PubMedHanley MJ et al. 2013, Br J Clin Pharmacol 75(4):1041-1052 (PMID 22943633; PMC3612722) — blueberry juice (50:50 lowbush and highbush) inhibited CYP3A and CYP2C9 in human liver microsomes (IC50 under 2%; not mechanism-based). In volunteers: buspirone AUC ratio with blueberry juice 1.39, not significant (grapefruit juice 2.12, significant); flurbiprofen AUC ratio 1.03 (fluconazole 1.71, significant). Authors: "no evidence for concern about clinically important pharmacokinetic drug interactions".
  • T1 · PubMedGalán-Ramírez G et al. 2025, J Trace Elem Med Biol 92:127753 (PMID 40967138) — 14 women aged 38-50, 5 mg iron as radio-labeled ferrous sulfate after an overnight fast. Iron absorbed (geometric mean): iron alone 30.2%; with 100 g fresh blueberries 6.8%; with blueberries and a standard breakfast 7.5%; with breakfast alone 5.7% (control vs each, p<0.0001). "fresh blueberries, with or without breakfast, significantly decreased non-heme iron absorption"; the authors call the findings preliminary.
  • T1 · PubMedSerafini M et al. 2009, Free Radic Biol Med 46(6):769-774 (PMID 19135520) — crossover, 11 healthy volunteers: 200 g blueberries with 200 mL water vs with 200 mL whole milk. With water, plasma antioxidant capacity rose (+6.1% and +11.1% on two measures) and plasma caffeic and ferulic acid rose. With milk there was no increase in plasma antioxidant capacity; peak caffeic acid −49.7%, peak ferulic acid −19.8%, and caffeic acid AUC was reduced (p<0.001).
  • T1 · PubMedOttaviani JI et al. 2023, Food Funct 14(18):8217-8228 (PMID 37615673; NCT03526094) — polyphenol oxidase activity across 18 foods (KU/100 g): banana 3258, beet greens 1594, red delicious apple 570, pear 147, strawberry 18, blueberry 12. In healthy men, cocoa extract flavan-3-ols in a mixed berry smoothie gave peak plasma metabolites of 659 ± 104 nmol/L, similar to a capsule (680 ± 78); in a banana smoothie, 96 ± 47 nmol/L. Funded by Mars, Inc.
  • T1 · PubMedCzank C et al. 2013, Am J Clin Nutr 97(5):995-1003 (PMID 23604435) — 8 men, 500 mg 13C-labeled cyanidin-3-glucoside: relative bioavailability 12.38 ± 1.38%; metabolites peaked at 10.25 h, present up to 48 h. Kalt W et al. 2014, J Agric Food Chem 62(18):3926-3934 (PMID 24432743) — 17 adults, 250 mL blueberry juice: parent anthocyanins 4%, metabolites 96% of urinary anthocyanins over 24 h. Rodriguez-Mateos A et al. 2012, J Agric Food Chem 60(23):5772-5778 (PMID 22175691) — 7 varieties analyzed.
  • T1 · PubMedRodriguez-Mateos A et al. 2019, J Gerontol A Biol Sci Med Sci 74(7):967-976 (PMID 30772905) — RCTs in healthy humans. Purified anthocyanins improved flow-mediated dilation dose-dependently, similar to wild blueberries with similar anthocyanin content; control drinks with fiber, minerals or vitamins had no significant effect. One month of daily wild blueberry raised it and lowered 24-h systolic blood pressure. Of 63 plasma metabolites, 14 and 21 correlated with acute and chronic improvements.
  • T1 · PubMedRodriguez-Mateos A et al. 2013, Am J Clin Nutr 98(5):1179-1191 (PMID 24004888; NCT01292954, NCT01829542) — two randomized, double-blind crossover trials in 21 healthy men. Flow-mediated dilation rose at 1-2 h and again at 6 h after a blueberry drink. At 1 h the effect increased with intake up to 766 mg total blueberry polyphenols, then plateaued; no significant difference between 766 and 1791 mg. Increases tracked circulating metabolites and lower neutrophil NADPH oxidase activity.
  • T1 · PubMedRodriguez-Mateos A et al. 2014, Mol Nutr Food Res 58(10):1952-1961 (PMID 25044909) — randomized controlled crossover, 10 healthy volunteers: blueberry baked products vs an unprocessed blueberry drink with the same amount of freeze-dried powder vs control baked products. Processing: anthocyanins −42%, chlorogenic acid +23%, total (poly)phenols not significantly changed. Flow-mediated dilation rose at 1, 2 and 6 h after the baked products "to a similar degree as the unprocessed blueberries".
  • T2 · NIH ODSNIH ODS Vitamin K Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/VitaminK-HealthProfessional; updated October 22, 2026), Table 2: "Blueberries, raw, ½ cup" 14 mcg phylloquinone, 12% of the 120 mcg Daily Value. Adequate Intake: 120 mcg men, 90 mcg women; no Upper Limit. "People who are taking warfarin and similar anticoagulants need to maintain a consistent intake of vitamin K". USDA FoodData Central 171711 (Blueberries, raw; SR Legacy): 19.3 mcg per 100 g; 1 cup = 148 g.
  • T2 · NIH ODSNIH ODS Manganese Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/Manganese-HealthProfessional; updated March 29, 2021), Table 2: "Blueberries, raw, ½ cup" 0.3 mg manganese, 13% of the 2.3 mg Daily Value. Adequate Intake, adults: 2.3 mg/day men, 1.8 mg/day women. Upper Limit, adults 19+: 11 mg/day. USDA FoodData Central 171711 (Blueberries, raw; SR Legacy), per 100 g: manganese 0.336 mg, fiber 2.4 g, vitamin C 9.7 mg, potassium 77 mg, 57 kcal; 1 cup = 148 g.
  • T3 · PubMedMuraki I et al. 2013, BMJ 347:f5001 (PMID 23990623) — 3 US cohorts, 187,382 adults: diabetes HR per 3 servings/week of blueberries 0.74 (0.66 to 0.83); fruit juice 1.08 (1.05 to 1.11). Cassidy A et al. 2013, Circulation 127(2):188-196 (PMID 23319811) — 93,600 women: top vs bottom fifth of anthocyanin intake, heart attack HR 0.68 (0.49 to 0.96); blueberries and strawberries >3/week, HR 0.66 (0.40 to 1.08). Devore EE et al. 2012, Ann Neurol 72(1):135-143 (PMID 22535616) — 16,010 older women.
  • T3 · PubMedJiang N et al. 2023, J Asthma Allergy 16:1253-1258 (PMID 38022748) — case report: a 12-year-old girl, anaphylaxis within 30 minutes of a breakfast that included blueberry; skin prick positive for blueberry, cherry, kiwifruit and pear; sensitized to lipid transfer proteins (mugwort Art v 3, peach Pru p 3). Gebhardt C et al. 2009, Allergy 64(3):498-499 (PMID 19220224) — case report, "10 kDa lipid transfer protein: the main allergenic structure in a German patient with anaphylaxis to blueberry".

BPC-157

  • T0 · Preliminary (in vitro / animal)He 2022, Front Pharmacol 13:1026182 (doi 10.3389/fphar.2022.1026182, PMID 36588717) — the only pharmacokinetic study: rats and beagle dogs, IV and IM, radiolabeled
  • T0 · Preliminary (in vitro / animal)Staresinic 2003, J Orthop Res 21:976 (doi 10.1016/S0736-0266(03)00110-4, PMID 14554208) — rat Achilles tendon transection, 10 µg–10 pg/kg i.p. daily; companion: Staresinic 2006 (PMID 16609979), rat quadriceps transection
  • T0 · Preliminary (in vitro / animal)Hsieh 2017, J Mol Med 95:323 (doi 10.1007/s00109-016-1488-y, PMID 27847966) — rat hind-limb ischemia + human endothelial cells, VEGFR2 mechanism
  • T0 · Preliminary (in vitro / animal)Chang 2014, Molecules 19:19066 (doi 10.3390/molecules191119066, PMID 25415472) — in vitro, rat tendon fibroblasts
  • T1 · PubMedVasireddi 2025, HSS J 21:485 (doi 10.1177/15563316251355551, PMID 40756949) — PRISMA systematic review, orthopaedic sports medicine use of BPC-157: 544 records screened, 36 included
  • T1.5 · Peptide Clinical PracticeMcGuire 2025, Curr Rev Musculoskelet Med 18:611 (doi 10.1007/s12178-025-09990-7, PMID 40789979) — clinical-practice narrative review, musculoskeletal use
  • T3 · PubMedLee 2021, Altern Ther Health Med 27(4):8 (PMID 34324435) — retrospective knee-pain case series, single private clinic, n=16 followed, 4 mg intra-articular BPC-157
  • T3 · PubMedLee 2024, Altern Ther Health Med 30(10):12 (PMID 39325560) — interstitial cystitis pilot, n=12 women, single 10 mg cystoscopic injection
  • T3 · PubMedLee 2025, Altern Ther Health Med 31(5):20 (PMID 40131143) — IV tolerability pilot, n=2, 10 then 20 mg IV over 1 h
  • T6 · FDA AdvisoryFDA 503A bulk drug substances action, Sept 29 2023 (Category 2 — significant safety risk) + subsequent nomination withdrawal (FDA "may present significant safety risks" page) + Warning Letter MARCS-CMS 655280 (Warrior Labz, June 12 2023)

Cacao PowderTheobroma cacao

  • T1 · PubMedOttaviani JI et al. 2023, Food Funct 14(18):8217-8228 (PMID 37615673; NCT03526094) — controlled, single-blinded crossover in healthy men. Cocoa extract flavan-3-ols taken as a capsule with 1% milk (541 mg), a mixed berry smoothie (484 mg) or a banana smoothie (638 mg; 177 g ripe frozen banana + almond milk). Peak plasma metabolites: 680 ± 78 (capsule), 659 ± 104 (berry), 96 ± 47 nmol/L (banana). Banana Cmax 84 ± 9% and AUC 81 ± 11% lower than capsule. Funded by Mars, Inc.
  • T1 · PubMedSesso HD et al. 2022, Am J Clin Nutr 115(6):1490-1500 (PMID 35294962; NCT02422745) — COSMOS: randomized, double-blind, placebo-controlled 2x2 factorial trial, 21,442 US adults (women ≥65, men ≥60), cocoa extract supplement (500 mg flavanols/day, including 80 mg (-)-epicatechin) or placebo, median 3.6 years. Total cardiovascular events: 410 vs 456, HR 0.90 (95% CI 0.78-1.02; P=0.11). Secondary: CVD death HR 0.73 (0.54-0.98); all-cause mortality HR 0.89 (0.77-1.03). No safety concerns.
  • T1 · PubMedBaker LD et al. 2023, Alzheimers Dement 19(4):1308-1319 (PMID 36102337) — COSMOS-Mind: 2262 participants (mean age 73; 60% women), cocoa extract (500 mg flavanols/day) or placebo and a multivitamin-mineral or placebo, 2x2 factorial, cognition assessed by telephone at baseline and annually for 3 years. Primary endpoint: cocoa extract had no effect on global cognition (mean z-score 0.03, 95% CI -0.02 to 0.08; P=.28). The multivitamin improved global cognition (z 0.07, 0.02 to 0.12; P=.007).
  • T1 · Cochrane ReviewRied K, Fakler P, Stocks NP 2017, Cochrane Database Syst Rev 4:CD008893 (PMID 28439881) — 35 trials (40 comparisons), 1804 mainly healthy adults, 2 to 18 weeks, 30 to 1218 mg flavanols/day (mean 670 mg) in 1.4 to 105 g of cocoa products. Systolic -1.76 mmHg (95% CI -3.09 to -0.43); diastolic -1.76 mmHg (-2.57 to -0.94). Systolic -4 mmHg in hypertensive participants (9 comparisons, 401 people); no significant difference in normotensive participants. Moderate-quality evidence.
  • T1 · PubMedHurrell RF, Reddy M, Cook JD 1999, Br J Nutr 81(4):289-95 (PMID 10999016) — iron absorption from a bread meal in adult subjects, measured by erythrocyte incorporation of radio-iron. All polyphenol-containing beverages inhibited absorption dose-dependently: 20-50 mg total polyphenols per serving reduced it 50-70%; 100-400 mg reduced it 60-90%. Inhibition: black tea 79-94%, peppermint tea 84%, pennyroyal 73%, cocoa 71%, vervain 59%, lime flower 52%, camomile 47%.
  • T1 · PubMedMullen W et al. 2009, Am J Clin Nutr 89(6):1784-91 (PMID 19403635) — 9 volunteers drank 250 mL of a cocoa beverage made with water or with milk (45 µmol (-)-epicatechin and (-)-catechin) after 2 days on a low-flavonoid diet. Milk did not affect gastric emptying or small-intestine transit and had only minor effects on plasma pharmacokinetics of flavan-3-ol metabolites, but lowered urinary excretion of 4 metabolites from 18.3% to 10.5% of the ingested dose (P=0.016).
  • T1 · PubMedSmit HJ, Gaffan EA, Rogers PJ 2004, Psychopharmacology (Berl) 176(3-4):412-9 (PMID 15549276) — two double-blind, placebo-controlled studies (n=20, n=22) of the amounts found in a 50 g bar of dark chocolate: 11.6 g cocoa powder, or caffeine 19 mg + theobromine 250 mg. Both gave identical improvements in "energetic arousal" and cognitive function versus placebo. Companion: Smit HJ, Blackburn RJ 2005, Psychopharmacology 181(1):101-6 (PMID 15772863), same doses, n=64.
  • T3 · PubMedMiller KB et al. 2008, J Agric Food Chem 56(18):8527-33 (PMID 18710243; The Hershey Company) — survey of commercial cocoa powders. Average total flavanols: natural 34.6 ± 6.8 mg/g; lightly alkalized 13.8 ± 7.3; medium 7.8 ± 4.0; heavily alkalized 3.9 ± 1.8 mg/g, falling linearly as pH rises. Tomas-Barberan FA et al. 2007, J Agric Food Chem 55(10):3926-35 (PMID 17439235) — an unfermented, non-roasted powder had 8 times more epicatechin; plasma epicatechin glucuronide was 5-fold higher in humans.
  • T3 · PubMedHands JM et al. 2024, Front Nutr 11:1366231 (PMID 39144282) — 72 dark chocolate and cocoa products bought in the USA in 2014, 2016, 2019 and 2022, tested for lead, cadmium and arsenic. 43% exceeded California Prop 65 maximum allowable dose levels for lead (0.5 mcg/day), 35% for cadmium (4.1 mcg/day), 0% for arsenic (10 mcg/day); 97.2% (70 of 72) were below FDA interim reference levels for lead. Median concentrations were below Prop 65 levels. Three authors worked for ConsumerLab.com.
  • T6 · FDA AdvisoryFDA Constituent Update, February 3, 2023: "FDA Announces Qualified Health Claim for Cocoa Flavanols in High Flavanol Cocoa Powder and Reduced Risk of Cardiovascular Disease" — enforcement discretion letter on a Barry Callebaut AG petition. FDA "determined that there is very limited credible scientific evidence" for the claim. Applies only to high flavanol cocoa powder with "at least 4% of naturally conserved cocoa flavanols" and foods containing it; not regular cocoa powder or chocolate.

Ciprofloxacin

  • T1 · PubMedPitman 2019, Antibiotics 8:108 (doi 10.3390/antibiotics8030108) — review of oral fluoroquinolone × multivalent cation interactions
  • T3 · PubMedNeuvonen 1991, Clin Pharmacol Ther 50:498 (doi 10.1038/clpt.1991.174) — crossover, n=7, ciprofloxacin 500 mg ± dairy
  • T3 · PubMedPolk 1989, Antimicrob Agents Chemother 33:1841 (doi 10.1128/AAC.33.11.1841) — n=12, ciprofloxacin 500 mg ± ferrous sulfate / multivitamin+zinc
  • T6 · FDA PrescribingFDA ciprofloxacin tablets prescribing label (Hikma SPL, §17 Patient Counseling / §12.3) — current
  • T6 · FDA PrescribingFDA ciprofloxacin label §12.3/§17 — caffeine (CYP1A2)

Collagen

  • T1 · PubMedPu 2023, Nutrients 15:2080 (PMID 37432180) — systematic review + meta-analysis, 26 RCTs, n=1721, hydrolyzed collagen for skin
  • T1 · PubMedMyung & Park 2025, Am J Med 138:1264 (doi 10.1016/j.amjmed.2025.04.034, PMID 40324552) — meta-analysis, 23 RCTs, n=1474, with funding-source and quality subgroups; non-industry authors (Korea NCC/Monash)
  • T1 · PubMedGarcía-Coronado 2019, Int Orthop 43:531 (doi 10.1007/s00264-018-4211-5, PMID 30368550) — meta-analysis of placebo-controlled RCTs, oral collagen for osteoarthritis
  • T1 · PubMedLugo 2016, Nutr J 15:14 (doi 10.1186/s12937-016-0130-8, PMID 26822714) — multicenter RCT, n=191 knee OA, UC-II 40 mg/d vs glucosamine 1500 mg + chondroitin 1200 mg vs placebo, 180 d; SPONSOR-RUN (InterHealth Nutraceuticals — sponsor's employees are first two authors)
  • T1 · PubMedOikawa 2020, Am J Clin Nutr 111:708 (doi 10.1093/ajcn/nqz332, PMID 31919527) — RCT, n=22 older women, 30 g whey vs 30 g collagen 2×/d, tracer-measured muscle protein synthesis; corroborated by Jacinto 2022 (PMID 35042187), 10-wk training RCT
  • T3 · PubMedProksch 2014, Skin Pharmacol Physiol 27:47 (doi 10.1159/000351376, PMID 23949208) — RCT, n=69 women 35–55, VERISOL 2.5 g or 5.0 g vs maltodextrin, 8 wk; product provided by GELITA AG, co-authors from the GELITA-linked Collagen Research Institute
  • T3 · PubMedClark 2008, Curr Med Res Opin 24:1485 (PMID 18416885) — RCT, 147 athletes with activity-related knee pain, 10 g collagen hydrolysate × 24 wk (GELITA AG employee co-author); companion Zdzieblik 2017, Appl Physiol Nutr Metab 42:588 (PMID 28177710) — n=139 athletes, 5 g/d × 12 wk, CRI co-author
  • T3 · PubMedKönig 2018, Nutrients 10:97 (PMID 29337906) — RCT, n=131 postmenopausal women with reduced BMD, 5 g specific collagen peptides (FORTIBONE, GELITA AG) vs maltodextrin, 12 months
  • T3 · PubMedShaw & Baar 2017, Am J Clin Nutr 105:136 (doi 10.3945/ajcn.116.138594, PMID 27852613) — double-blind crossover, n=8, vitamin C-enriched gelatin 5 or 15 g taken 1 h before 6 min of rope-skipping; NIH/university funded (not industry)
  • T3 · PubMedIwai 2005, J Agric Food Chem 53:6531 (PMID 16076145) — human PK, 9.4–23 g gelatin hydrolysates: peptide-form hydroxyproline in plasma; companion Shigemura 2011 (PMID 25212331, Hyp-Gly); rat 14C distribution: Watanabe-Kamiyama 2010 (PMID 19957932)

Creatine

  • T1 · PubMedLanhers 2017, Sports Med (doi 10.1007/s40279-016-0571-4, PMID 27328852) — meta-analysis, 53 double-blind placebo-controlled RCTs, n=1138, upper-limb strength
  • T1 · PubMedLanhers 2015, Sports Med (doi 10.1007/s40279-015-0337-4, PMID 25946994) — meta-analysis, 60 RCTs, n=1297, lower-limb strength
  • T1 · PubMedChilibeck 2017, Open Access J Sports Med 8:213 (doi 10.2147/OAJSM.S123529, PMID 29138605) — meta-analysis, 22 RCTs, n=721 older adults (mean ages 57–70) during resistance training
  • T1 · PubMedAvgerinos 2018, Exp Gerontol 108:166 (doi 10.1016/j.exger.2018.04.013, PMID 29704637) — systematic review of RCTs on cognition, 6 trials, n=281 healthy individuals
  • T1 · PubMedde Souza e Silva 2019, J Ren Nutr 29:480 (doi 10.1053/j.jrn.2019.05.004, PMID 31375416) — systematic review + meta-analysis, renal function (15 studies qualitative, 6 quantitative)
  • T1.5 · Peptide Clinical PracticeKreider 2017, J Int Soc Sports Nutr 14:18 (doi 10.1186/s12970-017-0173-z) — ISSN Position Stand: safety and efficacy of creatine supplementation
  • T1.5 · PubMedCommission Regulation (EU) 432/2012 annex (basis EFSA Journal 2011;9(7):2303) + Commission Implementing Regulation (EU) 2017/672 (basis EFSA Journal 2016;14(2):4400) — the two authorized EU health claims for creatine
  • T2 · NIH ODSNIH ODS, Dietary Supplements for Exercise and Athletic Performance — Health Professional Fact Sheet (ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional). No standalone creatine fact sheet exists — creatine is covered here
  • T3 · PubMedHultman 1996, J Appl Physiol 81:232 — muscle creatine loading PK, n=31 healthy men, biopsy-verified, 4 arms
  • T3 · PubMedvan der Merwe 2009, Clin J Sport Med 19:399 (doi 10.1097/JSM.0b013e3181b8b52f, PMID 19741313) — crossover, n=20 college rugby players, 25 g/d × 7 d then 5 g/d × 14 d

CurcuminCurcuma longa

  • T0 · PubMedShah BH et al. 1999, Biochem Pharmacol 58(7):1167-1172 (PMID 10484074) — in vitro: curcumin preferentially inhibited platelet-activating-factor- and arachidonic-acid-mediated platelet aggregation (IC50 ~20-25 uM) via inhibition of thromboxane A2 formation (IC50 ~70 uM) and Ca2+ signaling; no PKC involvement. Also inhibited epinephrine/ADP/collagen aggregation at higher concentrations.
  • T1 · PubMedDaily JW, Yang M, Park S. 2016, J Med Food 19(8):717-729 (PMID 27533649, PMC5003001) — systematic review/meta-analysis, 8 RCTs, ~1000 mg/day curcumin: pain VAS mean diff -2.04 (95% CI -2.85 to -1.24, P<.00001); WOMAC -15.36 (95% CI -26.9 to -3.77, P=.009); 5 studies found no significant difference vs pain medication. Authors: sample size/quality insufficient for definitive conclusions; call for larger RCTs.
  • T1 · PubMedShoba G et al. 1998, Planta Med 64(4):353-356 (PMID 9619120) — human volunteers: curcumin 2 g alone gave undetectable/very low serum levels; curcumin 2 g + piperine 20 mg raised serum concentration markedly at 0.25-1 h (P<0.01 at 0.25/0.5 h; P<0.001 at 1 h) — bioavailability increased 2000%. Mechanism: piperine inhibits hepatic + intestinal glucuronidation. Rats: +154%.
  • T3 · PubMedHalegoua-DeMarzio D et al. 2023, Am J Med 136(2):200-206 (PMID 36252717, PMC9892270) — DILIN, 10 adjudicated turmeric liver-injury cases (2004-2022): hepatocellular in 9, mixed in 1; latency 1-4 mo; 5 hospitalized, 1 died of acute liver failure. HLA-B*35:01 in 7/10 (2 homozygous; allele freq 0.450 vs 0.056-0.069 in controls). 3 of 7 tested products also contained piperine.

Doxycycline

  • T3 · PubMedNeuvonen 1970, Br Med J 4:532 — iron interference with tetracycline absorption in man
  • T6 · FDA AdvisoryFDA doxycycline (DORYX) prescribing label §7.3 / §17 / §12.3 / §2.1
  • T6 · FDA PrescribingFDA doxycycline label §7.3 — antacids/cations class statement

Furosemide

  • T3 · PubMedRieck 1999, J Lab Clin Med 134:238 (doi 10.1016/s0022-2143(99)90203-2) — furosemide increases urinary thiamine; + Seligmann 1991, Am J Med 91:151 (CHF thiamine deficiency)
  • T6 · PubMedFDA furosemide (Lasix) prescribing label — Precautions + Laboratory Tests + Drug Interactions

Ginkgo bilobaGinkgo biloba

  • T0 · Preliminary (in vitro / animal)National Toxicology Program Technical Report 578 (NIH Pub. 13-5920, March 2013) — 2-year corn-oil gavage studies of Ginkgo biloba extract, F344/N rats (100-1,000 mg/kg) and B6C3F1/N mice (200-2,000 mg/kg), 5 days/week: "clear evidence of carcinogenic activity" in mice (hepatocellular carcinoma, hepatoblastoma); "some evidence" in rats (thyroid follicular cell tumors). Summary: Rider CV et al. 2014, Toxicol Pathol 42(5):830-843 (doi 10.1177/0192623313501235).
  • T1 · PubMedDeKosky ST, Williamson JD, Fitzpatrick AL, et al. 2008, JAMA 300(19):2253-2262 (PMID 19017911, PMC2823569) — GEM double-blind RCT, n=3069 adults 75+ (2587 normal cognition, 482 MCI), ginkgo extract 120 mg twice daily vs placebo, median 6.1 y: dementia 277 vs 246 cases (3.3 vs 2.9 per 100 person-years), HR 1.12 (95% CI 0.94-1.33, P=.21); Alzheimer disease HR 1.16 (0.97-1.39). Not effective in reducing dementia or AD incidence.
  • T1 · PubMedBirks J, Grimley Evans J. 2009, Cochrane Database Syst Rev (1):CD003120 (PMID 19160216, doi 10.1002/14651858.CD003120.pub3) — 36 randomized double-blind trials in cognitive impairment or dementia; most small and under 3 months; 9 trials of 6 months (2016 patients). Recent trials inconsistent: of the four most recent, three found no difference from placebo and one found very large effects. No excess adverse events. Authors: evidence of benefit "is inconsistent and unreliable."
  • T1 · PubMedTan MS, Yu JT, Tan CC, et al. 2015, J Alzheimers Dis 43(2):589-603 (PMID 25114079) — meta-analysis, 9 RCTs of EGb 761 in cognitive impairment and dementia, 22-26 weeks, 2561 patients: cognition change scores favored EGb 761 (WMD -2.86, 95% CI -3.18 to -2.54); activities of daily living SMD -0.36 (-0.44 to -0.28); clinician global impression Peto OR 1.88 (1.54-2.29). Benefits mainly at 240 mg/day. No important safety concerns.
  • T1 · PubMedKellermann AJ, Kloft C. 2011, Pharmacotherapy 31(5):490-502 (PMID 21923430) — meta-analysis, 18 RCTs, 1985 adults, standardized ginkgo leaf extract vs placebo: no significant effect on ADP-induced platelet aggregation (WMD -0.35%, 95% CI -15.16 to 14.46), fibrinogen, aPTT (-0.42 sec, -0.97 to 0.12) or PT (SMD 0.00, -0.09 to 0.09); blood viscosity reduced (WMD -1.03 mPa·sec, -1.29 to -0.78). Conclusion: no indication of higher bleeding risk.
  • T1 · PubMedJiang X, Williams KM, Liauw WS, et al. 2005, Br J Clin Pharmacol 59(4):425-432 (PMID 15801937, PMC1884814) — open-label randomized three-way crossover, 12 healthy men, single 25 mg warfarin dose alone or with 7 days ginkgo pretreatment: S-warfarin clearance ratio 1.05 (90% CI 0.98-1.21); INR AUC ratio 0.93 (0.81-1.05). INR and platelet aggregation unaffected by ginkgo alone. No significant effect on warfarin pharmacokinetics or pharmacodynamics.
  • T1 · PubMedRobertson SM, Davey RT, Voell J, et al. 2008, Curr Med Res Opin 24(2):591-599 (PMID 18205997) — open-label, 14 healthy volunteers, 4 weeks standardized ginkgo extract: midazolam AUC -34% (p=0.03), Cmax -31%; lopinavir, ritonavir, fexofenadine unchanged. Opposite direction: Uchida S et al. 2006, J Clin Pharmacol 46(11):1290-1298 (PMID 17050793) — 10 healthy men, 360 mg/day for 28 days: midazolam AUC +25%, oral clearance -26%; tolbutamide AUC -16%.
  • T1 · PubMedZadoyan G, Rokitta D, Klement S, et al. 2012, Eur J Clin Pharmacol 68(5):553-560 (PMID 22189672, PMC3332346) — randomized three-way crossover cocktail study, 18 healthy adults, EGb 761 120 mg twice daily or 240 mg once daily for 8 days vs placebo: activity ratios near 1 for CYP1A2 (0.93), CYP2C9 (0.83), CYP2C19 (0.87), CYP2D6 (1.02), CYP3A (1.04). No relevant effect on major CYP enzymes. Sponsor: Dr. Willmar Schwabe (manufacturer); three authors are employees.
  • T1 · PubMedYin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. 2004, Pharmacogenetics 14(12):841-850 (PMID 15608563) — 18 healthy Chinese subjects genotyped for CYP2C19, omeprazole 40 mg before and after 12 days of ginkgo 140 mg twice daily: omeprazole plasma concentrations significantly decreased and 5-hydroxyomeprazole increased; the omeprazole/5-hydroxyomeprazole AUC ratio fell in all genotype groups, most in poor metabolizers.
  • T3 · PubMedStoddard GJ, Archer M, Shane-McWhorter L, et al. 2015, AMIA Annu Symp Proc 2015:1174-1183 (PMID 26958257, PMC4765589) — Veterans Administration records, warfarin patients: concurrent ginkgo associated with bleeding events, HR 1.38 (95% CI 1.20-1.58, p<.001). + Bent S et al. 2005, J Gen Intern Med 20(7):657-661 (PMID 16050865) — 15 published bleeding case reports, 8 intracranial; 13 had other bleeding risk factors; 6 documented no recurrence after stopping.
  • T3 · PubMedNaccarato M, Yoong D, Gough K. 2012, J Int Assoc Physicians AIDS Care 11(2):98-100 (PMID 22323244) — single case report: virological breakthrough in a patient maintained on the same efavirenz regimen for 10 years, attributed by the authors to a potential interaction with Ginkgo biloba (efavirenz is metabolized by CYP2B6 and, to a lesser extent, CYP3A4). Authors advise avoiding the combination when possible.
  • T3 · PubMedGranger AS. 2001, Age Ageing 30(6):523-525 (PMID 11742783) — two patients with well-controlled epilepsy had recurrent seizures within 2 weeks of starting Ginkgo biloba extract; seizure-free after stopping. + Kajiyama Y et al. 2002, Pediatrics 109(2):325-327 (PMID 11826216) — ginkgo SEED poisoning: 2-year-old with vomiting, then an afebrile convulsion 9 h after eating many seeds; serum 4-methoxypyridoxine 360 ng/mL; treated with pyridoxal phosphate.
  • T4 · NCCIHNCCIH, "Ginkgo: Usefulness and Safety" (nccih.nih.gov/health/ginkgo, February 2025) — no conclusive evidence that ginkgo helps any health condition; in three large studies it did not reduce dementia risk; possible modest benefit for dementia symptoms, evidence inconsistent; not helpful for hypertension, tinnitus, heart disease or MS symptoms. Side effects: dizziness, GI symptoms, headache. May increase bleeding risk with anticoagulants. Fresh seeds are toxic. May be unsafe in pregnancy.
  • T5 · EMA Herbal MonographEMA/HMPC, European Union herbal monograph on Ginkgo biloba L., folium (EMA/HMPC/321097/2012; adopted and published 2015; periodic review opened 2022) — two registrations. Well-established use: dry (acetone) leaf extract to improve age-related cognitive impairment and quality of life in adults with mild dementia. Traditional use: powdered leaf for heaviness of legs and cold hands and feet with minor circulatory problems. Adults only. Bleeding reported; consult a doctor if on blood thinners.

GinsengPanax ginseng

  • T1 · Cochrane ReviewGeng J, Dong J, Ni H, et al. 2010, Cochrane Database Syst Rev (12):CD007769 (PMID 21154383) — 9 randomized placebo-controlled trials (8 in healthy participants, 1 in memory impairment); only 5 had usable data; pooling impossible because outcomes, durations and doses differed. Some aspects of cognition, behavior and quality of life improved. No serious adverse events. Authors: "a lack of convincing evidence to show a cognitive enhancing effect of Panax ginseng in healthy participants."
  • T1 · Cochrane ReviewLee HW, Lee MS, Kim TH, et al. 2021, Cochrane Database Syst Rev 4(4):CD012654 (PMID 33871063, PMC8094213) — 9 placebo-controlled studies, 587 men with mild to moderate erectile dysfunction, up to 12 weeks: IIEF-15 erectile function MD 3.52 (95% CI 1.79-5.25; minimal important difference 4); IIEF-5 MD 2.39 (0.89-3.88; MID 5), both judged trivial. Self-reported ability to have intercourse RR 2.55 (1.76-3.69), low certainty. Adverse events RR 1.45 (0.69-3.03).
  • T1 · PubMedBach HV, Kim J, Myung SK, Cho YA. 2016, J Korean Med Sci 31(12):1879-1886 (PMID 27822924, PMC5102849) — meta-analysis, 12 RCTs, 630 participants: fatigue reduction SMD 0.34 (95% CI 0.16-0.52; 4 RCTs); physical performance SMD -0.01 (-0.29 to 0.27; 8 RCTs). Authors: "insufficient clinical evidence to support the use of ginseng supplements on reducing fatigue and enhancing physical performance" because trials are few and small.
  • T1 · PubMedShishtar E, Sievenpiper JL, Djedovic V, et al. 2014, PLoS One 9(9):e107391 (PMID 25265315, PMC4180277) — meta-analysis of 16 RCTs of ginseng (genus Panax) lasting 30 days or more: fasting blood glucose -0.31 mmol/L (95% CI -0.59 to -0.03, P=0.03; n=770); no significant effect on HbA1c, fasting insulin or HOMA-IR. + Komishon AM et al. 2016, J Hum Hypertens 30(10):619-626 (PMID 27074879) — 17 RCTs, n=1381: no significant effect on systolic, diastolic or mean arterial pressure.
  • T1 · PubMedCoon JT, Ernst E. 2002, Drug Saf 25(5):323-344 (PMID 12020172) — systematic review of safety data on Panax ginseng root extracts (5 databases, manufacturers, WHO and national schemes): in clinical trials adverse-event incidence with single-ingredient ginseng was similar to placebo; most common were headache, sleep and gastrointestinal disorders. Serious events appear in isolated case reports and with combination products. Possible interactions reported with warfarin, phenelzine and alcohol.
  • T1 · PubMedMalati CY, Robertson SM, Hunt JD, et al. 2012, J Clin Pharmacol 52(6):932-939 (PMID 21646440, PMC3523324) — open-label, 12 healthy adults, Panax ginseng 500 mg twice daily for 28 days: midazolam AUC ratio 0.66 (0.55-0.78), Cmax 0.74, half-life 0.71; fexofenadine (P-gp) unchanged. Contrast: Gurley BJ et al. 2005, Drugs Aging 22(6):525-539 (PMID 15974642) — 12 adults aged 60-76, 28 days: no change in CYP3A4, CYP1A2 or CYP2E1 phenotypes; CYP2D6 inhibited about 7%, not clinically relevant.
  • T1 · PubMedLee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. 2008, J Altern Complement Med 14(6):715-721 (PMID 18637764) — randomized open-label trial, 25 ischemic stroke patients starting warfarin, with or without Panax ginseng for 2 weeks: no significant difference in peak INR or in INR and PT areas under the curve. + Jiang X et al. 2004, Br J Clin Pharmacol 57(5):592-599 (PMID 15089812) — 12 healthy men: ginseng did not affect warfarin pharmacokinetics, INR or platelet aggregation.
  • T3 · PubMedBilgi N, Bell K, Ananthakrishnan AN, Atallah E. 2010, Ann Pharmacother 44(5):926-928 (PMID 20332334) — case report: 26-year-old man on imatinib 400 mg daily for 7 years without problems developed acute hepatitis (ALT 1069 U/L; biopsy favoring drug-induced injury) after 3 months of daily Panax ginseng in energy drinks. Both stopped; imatinib later restarted at the same dose without recurrence. Authors propose an interaction through CYP3A4; rated "probable" on the Horn scale.
  • T4 · NCCIHNCCIH, "Asian Ginseng" (nccih.nih.gov/health/asian-ginseng, February 2025) — may improve sexual function in erectile dysfunction; a small benefit for general fatigue; evidence for blood sugar control in diabetes inconclusive and conflicting; most research shows no improvement in athletic performance. Short-term oral use, up to 6 months, appears safe for most people; long-term safety questioned. Most common side effect: insomnia. Might lower blood sugar. May be unsafe in pregnancy.
  • T5 · EMA Herbal MonographEMA/HMPC, European Union herbal monograph on Panax ginseng C.A.Mey., radix, Revision 1 (EMA/HMPC/27744/2023, adopted 29 May 2024) — TRADITIONAL USE only, white and red ginseng: "Traditional herbal medicinal product for symptoms of asthenia such as fatigue and weakness." Use should not exceed 3 months; see a doctor if symptoms persist beyond 2 weeks. Not established under 18. Interactions: "None reported." Not recommended in pregnancy or lactation.

Glutathione

  • T1 · PubMedWitschi A, Reddy S, Stofer B, Lauterburg BH. 1992, Eur J Clin Pharmacol 43(6):667-669 (PMID 1362956) — 7 healthy volunteers, single oral glutathione 0.15 mmol/kg (~3 g): plasma glutathione, cysteine, and glutamate did NOT rise significantly over 270 min. Conclusion: "the systemic availability of glutathione is negligible in man" (hydrolyzed by intestinal/hepatic gamma-glutamyltransferase).
  • T1 · PubMedRichie JP et al. 2015, Eur J Nutr 54(2):251-263 (PMID 24791752) — 6-month double-blind RCT, 54 non-smoking adults, oral glutathione 250 or 1000 mg/day. At 6 mo, 1000 mg/d raised glutathione ~30-35% in erythrocytes/plasma/lymphocytes and ~260% in buccal cells; 250 mg/d ~17% blood / ~29% RBC. Whole-blood oxidized:reduced ratio fell. All returned to baseline after 1-month washout.
  • T1 · PubMedArjinpathana N, Asawanonda P. 2012, J Dermatolog Treat 23(2):97-102 (PMID 20524875) — randomized double-blind placebo-controlled, 60 healthy adults, oral glutathione 500 mg/day x 4 wk: melanin index fell at all 6 sites but was significantly lower than placebo at only 2 sites (right face p=0.021, left forearm p=0.036). Well tolerated. Authors: effect in "a small number of subjects"; long-term safety not established; larger trials needed.
  • T4 · PubMedSonthalia S, Daulatabad D, Sarkar R. 2016, Indian J Dermatol Venereol Leprol 82(3):262-272 (PMID 27088927) — review: mechanism is tyrosinase inhibition + eumelanin→phaeomelanin shift; 3 RCTs support modest oral/topical lightening with good safety; INTRAVENOUS glutathione has NO evidence of efficacy for skin whitening despite popularity, has caused adverse effects, and the Philippine FDA issued a public warning against its off-label use for skin lightening. Promotion likely commercially driven.

Hydrochlorothiazide

  • T3 · PubMedStørmer 1993, Food Chem Toxicol 31:303 (PMID 8386690) — glycyrrhizin/licorice pseudohyperaldosteronism (additive hypokalemia)
  • T6 · FDA PrescribingFDA hydrochlorothiazide prescribing label — Precautions/General + Adverse Reactions

Isocarboxazid

  • T3 · PubMedVan den Eynde/Gillman 2022 modernized MAOI diet vs the Marplan label's conservative list
  • T6 · FDA PrescribingFDA isocarboxazid (Marplan) prescribing label (rev. Dec 2025) — CONTRAINDICATIONS (tyramine foods)

KavaPiper methysticum

  • T0 · Preliminary (in vitro / animal)Chua 2016, PLoS One 11:e0157700 (PMID 27332705) — kavain at recombinant GABA-A receptors
  • T0 · Preliminary (in vitro / animal)Zhou 2010, FASEB J 24:4722 (PMID 20696856) — flavokawain B hepatotoxicity (in vitro + mouse)
  • T2 · Codex AlimentariusCXS 336R-2020 — Codex regional standard for kava products for use as a beverage when mixed with water (adopted CAC43, Sept 25 2020)
  • T3 · PubMedMathews 2002, Drug Metab Dispos 30:1153 — kava extract/kavalactones vs human CYP450 in vitro; in vivo companion: Gurley 2005, Clin Pharmacol Ther 77:415 (PMID 15900287)
  • T3 · PubMedAlmeida & Grimsley 1996, Ann Intern Med 125:940 (PMID 8967683) — coma from kava + alprazolam
  • T3 · PubMedSarris 2013, Traffic Inj Prev 14:13 (PMID 23259514) — driving simulator, kava 180 mg kavalactones vs oxazepam vs placebo; Aporosa 2022, J Ethnopharmacol 291:115080 (PMID 35151837) — traditional sessions (~6 h, ~3.6 L)
  • T3 · PubMedNorton & Ruze 1994, J Am Acad Dermatol 31:89 (PMID 8021378) — kava dermopathy; Clough 2003, Intern Med J 33:336 (PMID 12895162) — heavy-use biochemistry, Arnhem Land, n=101
  • T4 · NCCIHNCCIH, "Kava — Usefulness and Safety" (nccih.nih.gov/health/kava, updated April 2025)
  • T6 · FDA AdvisoryFDA CFSAN Scientific Memorandum: Kava, Aug 11 2020 (fda.gov/media/169556/download) — the agency's position on BEVERAGE/conventional-food use; context: the 2002 supplement advisory (archived, unrevised)

Kava ExtractPiper methysticum

  • T0 · Preliminary (in vitro / animal)Chua 2016, PLoS One 11:e0157700 (PMID 27332705) — kavain at GABA-A receptors
  • T0 · Preliminary (in vitro / animal)Zhou 2010, FASEB J 24:4722 (PMID 20696856) — flavokawain B hepatotoxicity (in vitro + mouse)
  • T1 · Cochrane ReviewPittler & Ernst 2003, Cochrane CD003383 (PMID 12535473) — kava extract for anxiety: 11 RCTs, n=645
  • T1 · PubMedSarris 2013, J Clin Psychopharmacol 33:643 (PMID 23635869) — DB-RCT, n=75, aqueous dried-root extract 120/240 mg kavalactones/d × 6 wk, GAD
  • T1 · PubMedSarris 2020, Aust N Z J Psychiatry 54:288 (PMID 31813230) — Phase III, n=171 GAD, aqueous extract 240 mg kavalactones/d × 16 wk — largest and longest kava trial
  • T1 · PubMedOoi 2018, J Altern Complement Med 24:770 (PMID 29641222) — GAD meta; Smith & Leiras 2018, Complement Ther Clin Pract 33:107 (PMID 30396607) — responder-rate meta, 11 trials
  • T1.5 · PubMedBandelow 2008, WFSBP anxiety guidelines (first revision), World J Biol Psychiatry 9:248
  • T3 · PubMedAlmeida & Grimsley 1996, Ann Intern Med 125:940 (PMID 8967683) — coma from kava + alprazolam
  • T3 · PubMedTeschke 2008, Eur J Gastroenterol Hepatol 20:1182 (PMID 18989142) — CIOMS/RUCAM assessment of the 26 German/Swiss regulatory cases
  • T3 · PubMedMathews 2002, Drug Metab Dispos 30:1153 — kava extract/kavalactones vs human CYP450 in vitro; in vivo: Gurley 2005 (PMID 15900287), n=12, 28 d supplement dosing
  • T4 · NCCIHNCCIH, "Kava — Usefulness and Safety" (April 2025)
  • T6 · FDA AdvisoryFDA/CFSAN consumer advisory, March 25 2002: "Kava-Containing Dietary Supplements May Be Associated With Severe Liver Injury" (archived; never revised or withdrawn) + CFSAN Scientific Memorandum, Aug 11 2020

KratomMitragyna speciosa

  • T0 · Preliminary (in vitro / animal)Kruegel 2019, ACS Cent Sci 5:992 (doi 10.1021/acscentsci.9b00141) — 7-OH as active metabolite of mitragynine (mouse in vivo; mouse + human liver preparations)
  • T0 · Preliminary (in vitro / animal)Todd 2020, Sci Rep 10:19158 (doi 10.1038/s41598-020-76119-w) — receptor pharmacology, human µ-opioid receptor in vitro
  • T1 · PubMedVicknasingam 2020, Yale J Biol Med 93:229 (PMID 32607084) — randomized, placebo-controlled, double-blind cold-pressor study, n=26 male daily kratom users (mean 6.1 y use), kratom decoction vs placebo
  • T3 · PubMedKamble 2020, Toxicol Lett 319:148 (doi 10.1016/j.toxlet.2019.11.005) — CYP inhibition screening, human liver microsomes; NIDA-funded (UG3 DA048353, R01 DA047855), no industry conflicts
  • T3 · PubMedTanna 2023, Drug Metab Dispos 51:923 (doi 10.1124/dmd.122.001005) — NCCIH/NIDA Natural Product Drug Interaction center; time-dependent CYP3A inhibition + transporters
  • T3 · PubMedTanna RS et al. 2023, Clin Pharmacol Ther 113(6):1315-1325 (PMID 36924284) — 12 healthy adults, single low dose of kratom tea (2 g) with the CYP3A probe midazolam (2.5 mg) and the CYP2D6 probe dextromethorphan (30 mg). Dextromethorphan AUC ratio 0.99 (90% CI 0.83-1.19), Cmax 0.96 (0.78-1.19): no effect. Midazolam AUC 1.39 (1.23-1.57), Cmax 1.50 (1.32-1.70); half-life unchanged (1.07), pointing to intestinal CYP3A inhibition. First clinical evaluation of kratom's drug interaction potential.
  • T3 · PubMedOlsen 2019, MMWR 68:326 (doi 10.15585/mmwr.mm6814a2) — CDC SUDORS, unintentional overdose deaths with kratom detected, 27 states, Jul 2016–Dec 2017
  • T3 · PubMedNavarro 2019, DILIN Prospective Study case series (AASLD abstract 0212, Hepatology) — kratom hepatotoxicity among 404 herbal/dietary-supplement liver-injury cases, 2004–2018
  • T6 · FDA AdvisoryFDA Import Alert 54-15 (accessdata.fda.gov/cms_ia/importalert_1137.html) — detention without physical examination of kratom-containing dietary products; first issued Feb 2014, actively updated (Red List addition 08/17/2026)
  • T6 · FDA AdvisoryFDA, "FDA and Kratom" (fda.gov/news-events/public-health-focus/fda-and-kratom; content current 12/02/2025)
  • T6 · DEA ScheduleDEA, 81 FR 59929 (Aug 31, 2016, Docket DEA-442) notice of intent to place mitragynine + 7-OH in Schedule I — WITHDRAWN at 81 FR 70652 (Oct 13, 2016, Docket DEA-442W)
  • T6 · FDA PrescribingFDA Adderall (mixed amphetamine salts) tablets prescribing information, DailyMed, updated May 29, 2024 — Metabolism: "CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine." Drug Interactions, CYP2D6 Inhibitors: concomitant use "may increase the exposure of Adderall compared to the use of the drug alone and increase the risk of serotonin syndrome"; "Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome." Kratom is not named on the label.

Kratom ExtractMitragyna speciosa

  • T0 · Preliminary (in vitro / animal)Kruegel 2019, ACS Cent Sci 5:992 (doi 10.1021/acscentsci.9b00141) — 7-OH as active metabolite of mitragynine (mouse in vivo; mouse + human liver preparations)
  • T0 · Preliminary (in vitro / animal)Todd 2020, Sci Rep 10:19158 (doi 10.1038/s41598-020-76119-w) — receptor pharmacology, human µ-opioid receptor in vitro
  • T3 · PubMedKamble 2020, Toxicol Lett 319:148 (doi 10.1016/j.toxlet.2019.11.005) — CYP inhibition screening, human liver microsomes; NIDA-funded (UG3 DA048353, R01 DA047855), no industry conflicts
  • T3 · PubMedTanna 2023, Drug Metab Dispos 51:923 (doi 10.1124/dmd.122.001005) — NCCIH/NIDA Natural Product Drug Interaction center; time-dependent CYP3A inhibition + transporters
  • T3 · PubMedTanna RS et al. 2023, Clin Pharmacol Ther 113(6):1315-1325 (PMID 36924284) — 12 healthy adults, single low dose of kratom tea (2 g) with the CYP3A probe midazolam (2.5 mg) and the CYP2D6 probe dextromethorphan (30 mg). Dextromethorphan AUC ratio 0.99 (90% CI 0.83-1.19), Cmax 0.96 (0.78-1.19): no effect. Midazolam AUC 1.39 (1.23-1.57), Cmax 1.50 (1.32-1.70); half-life unchanged (1.07), pointing to intestinal CYP3A inhibition. First clinical evaluation of kratom's drug interaction potential.
  • T3 · PubMedOlsen 2019, MMWR 68:326 (doi 10.15585/mmwr.mm6814a2) — CDC SUDORS, unintentional overdose deaths with kratom detected, 27 states, Jul 2016–Dec 2017
  • T3 · PubMedNavarro 2019, DILIN Prospective Study case series (AASLD abstract 0212, Hepatology) — kratom hepatotoxicity among 404 herbal/dietary-supplement liver-injury cases, 2004–2018
  • T6 · DEA ScheduleDEA, 81 FR 59929 (Aug 31, 2016, Docket DEA-442) notice of intent to place mitragynine + 7-OH in Schedule I — WITHDRAWN at 81 FR 70652 (Oct 13, 2016, Docket DEA-442W)
  • T6 · FDA AdvisoryFDA, "FDA and Kratom" (fda.gov/news-events/public-health-focus/fda-and-kratom; content current 12/02/2025)
  • T6 · FDA AdvisoryFDA Import Alert 54-15 (accessdata.fda.gov/cms_ia/importalert_1137.html) — detention without physical examination of kratom-containing dietary products; first issued Feb 2014, actively updated (Red List addition 08/17/2026)
  • T6 · FDA PrescribingFDA Adderall (mixed amphetamine salts) tablets prescribing information, DailyMed, updated May 29, 2024 — Metabolism: "CYP2D6 is known to be involved with formation of 4-hydroxy-amphetamine." Drug Interactions, CYP2D6 Inhibitors: concomitant use "may increase the exposure of Adderall compared to the use of the drug alone and increase the risk of serotonin syndrome"; "Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome." Kratom is not named on the label.

Levofloxacin

  • T1 · PubMedPitman 2019, Antibiotics 8:108 (doi 10.3390/antibiotics8030108), Table 1 (attributing Shiba 1992) — levofloxacin × cations
  • T3 · PubMedFish & Chow 1997, Clin Pharmacokinet 32:101 (PMID 9068926) — levofloxacin clinical pharmacokinetics
  • T6 · FDA PrescribingFDA levofloxacin tablets prescribing label (§2.4 / §7.1) — current

Levothyroxine

Linezolid

  • T6 · FDA PrescribingFDA linezolid (Zyvox) prescribing label — Drug Interactions + §17 counseling
  • T6 · FDA AdvisoryFDA linezolid label (serotonin syndrome) + FDA Drug Safety Communication on methylene blue (2011-07-26, a second hidden MAOI)

Lion's ManeHericium erinaceus

  • T0 · Preliminary (in vitro / animal)Mori K et al. 2008, Biol Pharm Bull 31(9):1727-32 (PMID 18758067) — H. erinaceus ethanol extract raised NGF mRNA and NGF protein secretion in 1321N1 human astrocytoma cells through JNK signaling; hericenones C, D and E did not; mice fed 5% dry powder for 7 days had higher hippocampal NGF mRNA. Lai PL et al. 2013, Int J Med Mushrooms 15(6):539-54 (PMID 24266378) — aqueous extract induced NGF secretion and neurite outgrowth in NG108-15 cells but did not protect them from oxidative stress.
  • T0 · Preliminary (in vitro / animal)Mori K et al. 2010, Phytomedicine 17(14):1082-5 (PMID 20637576) — hericenone B, isolated from H. erinaceus ethanol extract, inhibited collagen-induced platelet aggregation in washed rabbit platelets and in human platelets; aggregation induced by ADP, thrombin, adrenaline or arachidonic acid was not inhibited. Poniedzialek B et al. 2019, Nutrients 11(12):3040 (PMID 31842490) — hot-water extracts of eight edible mushrooms including H. erinaceus: none altered prothrombin time or INR in vitro.
  • T0 · Preliminary (in vitro / animal)Liang B et al. 2013, BMC Complement Altern Med 13:253 (PMID 24090482) — streptozotocin-diabetic Wistar rats given aqueous extract of H. erinaceus at 100 or 200 mg/kg for 28 days: significantly lower serum glucose, higher serum insulin, improved lipid measures, and higher liver antioxidant enzyme activity (CAT, SOD, GSH-Px) with lower MDA, compared with untreated diabetic rats.
  • T1 · PubMedMori K et al. 2009, Phytother Res 23(3):367-72 (PMID 18844328) — double-blind, placebo-controlled trial, 30 Japanese adults aged 50-80 with mild cognitive impairment, 15 per group: 3 g/day of tablets (96% Yamabushitake dry powder) for 16 weeks. Scores on a cognitive function scale based on the Revised Hasegawa Dementia Scale were significantly higher than placebo at weeks 8, 12 and 16, then fell significantly 4 weeks after intake stopped. Laboratory tests showed no adverse effect.
  • T1 · PubMedSaitsu Y et al. 2019, Biomed Res 40(4):125-131 (PMID 31413233) — randomized, double-blind, placebo-controlled parallel-group study of supplements containing H. erinaceus fruiting body for 12 weeks, with three cognitive tests: Mini Mental State Examination (MMSE), Benton visual retention test, and Standard verbal paired-associate learning test. Only the MMSE showed a significant improvement with H. erinaceus; the other two tests did not.
  • T1 · PubMedLi IC et al. 2020, Front Aging Neurosci 12:155 (PMID 32581767; NCT04065061) — pilot double-blind trial, 49 patients with mild Alzheimer's disease randomized (41 completed): three 350 mg capsules/day of erinacine A-enriched H. erinaceus mycelia (5 mg/g erinacine A) or placebo for 49 weeks. Between groups at week 49: IADL 6.7 vs 5.0 (p=0.012); CASI 75.35 vs 69.67 (p=0.315); MMSE 23.2 vs 20.67 (p=0.261). Four dropouts for side effects (3 active, 1 placebo).
  • T1 · PubMedDocherty S et al. 2023, Nutrients 15(22):4842 (PMID 38004235) — double-blind pilot, 41 healthy adults aged 18-45, 1.8 g/day for 28 days: faster Stroop task 60 min after one dose (p=0.005); trend to lower stress (p=0.051); null and some negative findings. Surendran G et al. 2025, Front Nutr 12:1405796 (PMID 40276537) — crossover, 18 adults, one 3 g dose of 10:1 fruiting body extract: no effect on composite cognition or mood. Grozier CD et al. 2022 (PMID 36582308) — 10 g/day, 4 weeks: no effect.
  • T1 · PubMedNagano M et al. 2010, Biomed Res 31(4):231-7 (PMID 20834180) — 30 women randomized to H. erinaceus cookies or placebo cookies for 4 weeks: depression (CES-D) and indefinite complaints scores fell from baseline with H. erinaceus; against placebo, only two complaint items differed. Vigna L et al. 2019, Evid Based Complement Alternat Med 2019:7861297 (PMID 31118969) — 77 overweight or obese adults on a low-calorie diet, 8 weeks: depression, anxiety and sleep scores improved; BDNF unchanged.
  • T1 · PubMedMenon A et al. 2025, Front Nutr 12:1641246 (PMID 40959699; PROSPERO CRD42024571250) — systematic review, PubMed search January 2000 to June 2024: 5 randomized controlled trials, 3 pilot clinical trials, 1 cohort study, 1 case report, 15 laboratory studies and 1 computer analysis. MMSE from one RCT and one pilot trial: combined weighted mean increase of 1.17 in the intervention group. Potential side effects, commonly unreported: stomach discomfort, headache and allergic reactions.
  • T3 · PubMedNakatsugawa M et al. 2003, Intern Med 42(12):1219-22 (PMID 14714963) — case report: 63-year-old man with acute respiratory distress syndrome and diffuse lung infiltrates; lymphocyte stimulation test strongly reactive to an H. erinaceum extract product; recovered with steroid pulse therapy under mechanical ventilation. Maes MF et al. 1999, Contact Dermatitis 40(5):289-90 (PMID 10344494) — occupational allergic contact dermatitis from the mushroom (title only; the record has no abstract).
  • T3 · PubMedNIH LiverTox, "Lion's Mane" (NBK599740, last update January 5, 2024) — not linked to serum enzyme elevations during therapy or to clinically apparent liver injury; not listed in large case series or systematic reviews of herbal liver injury. Likelihood score E (unlikely cause of clinically apparent liver injury). In trials of prolonged use, mild abdominal discomfort, nausea or diarrhea, usually in under 10% of subjects. Most purported effects were shown in cell culture or animals, not in humans.
  • T6 · FDA AdvisoryFDA Warning Letter CMS 659735 to Lone Star Botanicals Inc. (Tyler, TX), November 6, 2023 — an organic lion's mane mushroom powder was found to be an unapproved new drug (FD&C Act sections 201(p), 505(a)) and a misbranded drug (section 502(f)(1)) on the basis of website, label and brochure claims: guarding against dementia, reducing depression and anxiety, helping regulate diabetes, anti-inflammatory and anti-cancer properties, and treating psoriasis and eczema.

Lisinopril

  • T1 · PubMedLapi 2013, BMJ 346:e8525 (doi 10.1136/bmj.e8525, PMID 23299844) — the NSAID "triple whammy" AKI, nested case-control, 487,372 patients
  • T6 · FDA PrescribingFDA lisinopril prescribing label §5.5 (Hyperkalemia) / §7.1 / §12.1 / §17
  • T6 · FDA PrescribingFDA lisinopril label §6.1 (cough) + §7.5 (lithium)

Losartan

  • T6 · FDA PrescribingFDA losartan prescribing label §5.4 (Hyperkalemia) / §7.1 / §17
  • T6 · FDA PrescribingFDA losartan label §6.1 (cough rechallenge) + §7.2 (lithium)

Lovastatin

  • T1 · PubMedBailey 2013, CMAJ 185:309 (PMID 23184849) — grapefruit mechanism (shared with simvastatin anchor A2)
  • T6 · FDA PrescribingFDA lovastatin (Mevacor) prescribing label — Clinical Pharmacology + Table I + Table VII + Precautions

Maca rootLepidium meyenii

  • T1 · PubMedGonzales GF et al. 2003, J Endocrinol 176(1):163-168 (PMID 12525260) — 12-week double-blind placebo-controlled RCT, healthy men 21-56, gelatinized maca 1.5 or 3.0 g/day vs placebo (hormones at wk 0,2,4,8,12): serum LH, FSH, testosterone, estradiol, prolactin, and 17-OH-progesterone did NOT change vs placebo or over time. Conclusion: "treatment with Maca does not affect serum reproductive hormone levels."
  • T1 · PubMedShin BC, Lee MS, Yang EJ, Lim HS, Ernst E. 2010, BMC Complement Altern Med 10:44 (PMID 20691074, PMC2928177) — systematic review, 4 RCTs: significant benefit for sexual desire/function in two (healthy menopausal women; healthy adult men) and in one erectile-dysfunction trial (IIEF-5); no effect in one (healthy cyclists). Authors: few trials, small total sample, limited methodological quality — firm conclusions cannot be drawn; more rigorous studies warranted.

Magnesium Glycinate

  • T1 · PubMedMah & Pitre 2021, BMC Complement Med Ther 21:125 (doi 10.1186/s12906-021-03297-z, PMID 33865376) — systematic review + meta-analysis, magnesium for insomnia: 3 RCTs, n=151 older adults
  • T1 · PubMedZhang 2016, Hypertension 68:324 (doi 10.1161/HYPERTENSIONAHA.116.07664, PMID 27402922) — meta-analysis, 34 double-blind placebo-controlled RCTs, n=2028, median 368 mg/d × 3 mo
  • T1 · Cochrane ReviewGarrison 2020, Cochrane CD009402 (doi 10.1002/14651858.CD009402.pub3, PMID 32956536) — 11 RCTs, n=735, magnesium for skeletal muscle cramps
  • T1 · PubMedDai Q et al. 2018, Am J Clin Nutr 108(6):1249-1258 (PMID 30541089; NCT03265483) — 180 adults aged 40-85, NCI-funded study nested in a double-blind randomized trial of magnesium vs placebo (doses customized to dietary intake). Magnesium raised 25(OH)D3 when baseline 25(OH)D was close to 30 ng/mL and lowered it when baseline was higher (about 30 to 50 ng/mL). Deng X et al. 2013, BMC Med 11:187 (PMID 23981518) — NHANES: higher magnesium intake associated with lower risk of vitamin D deficiency.
  • T1.5 · PubMedHolland 2012, AAN/AHS evidence-based guideline update, Neurology 78:1346 (doi 10.1212/WNL.0b013e3182535d0c, PMID 22529203) — episodic migraine prevention
  • T2 · NIH ODSNIH ODS Magnesium Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/Magnesium-HealthProfessional)
  • T2 · NIH ODSNIH ODS Magnesium Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/Magnesium-HealthProfessional; updated January 6, 2026), Magnesium and Health, Osteoporosis: "Magnesium also affects the concentrations of both parathyroid hormone and the active form of vitamin D, which are major regulators of bone homeostasis."
  • T3 · PubMedAbbasi 2012, J Res Med Sci 17:1161 (PMID 23853635) — double-blind RCT, n=46 elderly primary insomnia, 500 mg/d × 8 wk
  • T3 · PubMedSchuette 1994, JPEN 18:430 (doi 10.1177/0148607194018005430, PMID 7815675) — double-blind crossover, n=12 ileal-resection patients, 26Mg-labeled bisglycinate vs oxide
  • T3 · PubMedSupakatisant & Phupong 2015, Matern Child Nutr 11:139 (doi 10.1111/j.1740-8709.2012.00440.x, PMID 22909270) — double-blind RCT, n=86 pregnant women with leg cramps, magnesium BISGLYCINATE 300 mg/d × 4 wk
  • T3 · PubMedPeikert 1996, Cephalalgia 16:257 (PMID 8792038) — RCT, n=81 migraineurs, 600 mg/d elemental (trimagnesium dicitrate) × 12 wk
  • T3 · PubMedWalker 2003, Magnes Res 16:183 (PMID 14596323) — RCT n=46, citrate vs amino-acid chelate vs oxide, 300 mg/d × 60 d; companions: Firoz & Graber 2001 (PMID 11794633, oxide fractional absorption 4%), Lindberg 1990 (PMID 2407766, citrate ≫ oxide solubility/urinary response)
  • T3 · PubMedTarleton 2017, PLoS ONE 12:e0180067 (PMID 28654669) — open-label randomized crossover, n=126, 248 mg/d elemental (as chloride) × 6 wk, mild-moderate depression; companion: Boyle 2017 SR, Nutrients 9:429 (PMID 28445426), anxiety
  • T3 · PubMedUwitonze AM, Razzaque MS 2018, J Am Osteopath Assoc 118(3):181-189 (PMID 29480918) — narrative review: "All of the enzymes that metabolize vitamin D seem to require magnesium, which acts as a cofactor in the enzymatic reactions in the liver and kidneys." It concludes that the recommended amount of magnesium should be consumed to obtain the optimal benefits of vitamin D. Dai 2018 (PMID 30541089) describes the same basis as "previous in vitro and in vivo studies".
  • T3 · PubMedFatemi S et al. 1991, J Clin Endocrinol Metab 73(5):1067-72 (PMID 1939521) — 26 normal subjects on a 3-week low-magnesium diet (under 1 meq/day): serum magnesium fell from 0.80 to 0.61 mmol/L, serum 1,25-dihydroxyvitamin D fell from 55 ± 4 to 43 ± 3 pmol/L (P<0.05), and PTH secretion was impaired. Rude RK et al. 1985, J Clin Endocrinol Metab 61(5):933-40 (PMID 3840173) — 23 hypocalcemic magnesium-deficient patients: 16 had low 1,25-(OH)2D; 25-OHD did not change with magnesium therapy.
  • T6 · FDA AdvisoryFDA Drug Safety Communication, March 2, 2011 — low serum magnesium associated with long-term proton-pump-inhibitor use (fda.gov)

Melatonin

  • T1 · PubMedHärtter S et al. 2000, Clin Pharmacol Ther 67:1 (PMID 10668847) — healthy-volunteer PK study, oral melatonin with vs without fluvoxamine coadministration
  • T1 · PubMedvon Bahr C, Ursing C, Hartter S et al. 2000, Eur J Clin Pharmacol — "Fluvoxamine but not citalopram increases serum melatonin in healthy subjects," evidence CYP1A2 and CYP2C19 hydroxylate melatonin
  • T1 · PubMedErland LA, Saxena PK 2017, J Clin Sleep Med 13(2):275 (PMID 27855744) — analytical content study of 31 commercial melatonin supplements; + 2023 gummy analysis (per NCCIH)
  • T2 · NCCIHNCCIH, "Melatonin: What You Need To Know" (nccih.nih.gov; updated May 2024)
  • T3 · PubMedLusardi P et al. 2000 — melatonin + nifedipine GITS in hypertensive patients; dihydropyridine calcium-channel-blocker antagonism
  • T6 · FDA AdvisoryFDA — melatonin regulated as a dietary supplement in the US (no pre-market dose approval; OTC at any dose)

Metformin

  • T1 · PubMedAroda 2016, J Clin Endocrinol Metab 101:1754 (doi 10.1210/jc.2015-3754, PMID 26900641) — DPP/DPPOS, metformin and B12
  • T3 · PubMedBauman 2000, Diabetes Care 23:1227 (PMID 10977010) — oral calcium reverses metformin-induced B12 malabsorption
  • T6 · FDA PrescribingFDA metformin prescribing label §5.2 (Vitamin B12 Deficiency)

Milk ThistleSilybum marianum

  • T0 · Preliminary (in vitro / animal)Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. 2004, Drug Metab Dispos 32(6):587-594 (PMID 15155549) — in vitro, purified recombinant enzymes: silybin inactivated CYP3A4 (KI 32-166 microM) and CYP2C9 (KI 5 microM) in a mechanism-based manner and inhibited UGT1A1 (IC50 1.4 microM), with weaker inhibition of UGT1A6, 1A9, 2B7 and 2B15. Authors: clinical significance of UGT1A1 inhibition unknown.
  • T1 · PubMedRambaldi A, Jacobs BP, Gluud C. 2007, Cochrane Database Syst Rev (4):CD003620 (PMID 17943794, PMC8724782) — 18 randomized trials, 1088 patients with alcoholic and/or hepatitis B or C liver disease; only 28.6% of trials high quality. Milk thistle vs placebo or no intervention: all-cause mortality RR 0.78 (95% CI 0.53-1.15); complications RR 0.95 (0.83-1.09); no effect on liver histology. Liver-related mortality RR 0.50 (0.29-0.88) in all trials but 0.57 (0.28-1.19) in high-quality trials.
  • T1 · PubMedFried MW, Navarro VJ, Afdhal N, et al. (SyNCH Study Group). 2012, JAMA 308(3):274-282 (PMID 22797645, PMC3683986) — multicenter double-blind RCT, 154 adults with chronic hepatitis C and ALT 65 U/L or more after failed interferon therapy; silymarin 420 mg or 700 mg three times daily vs placebo, 24 weeks: primary ALT outcome met by 2 participants per group (3.8%, 4.0%, 3.8%; P≥.99); no difference in ALT decline (P=.75) or HCV RNA (P=.54). Adverse events comparable with placebo.
  • T1 · PubMedWah Kheong C, Nik Mustapha NR, Mahadeva S. 2017, Clin Gastroenterol Hepatol 15(12):1940-1949 (PMID 28419855) — double-blind RCT, 99 adults with biopsy-proven NASH, silymarin 700 mg three times daily vs placebo, 48 weeks: primary outcome (30%+ fall in NAFLD activity score) 32.7% vs 26.0% (P=.467); fibrosis improved by 1 point or more in 22.4% vs 6.0% (P=.023). + Navarro VJ et al. 2019, PLoS One 14(9):e0221683 (PMID 31536511) — 78 US patients, 48 weeks: primary endpoint 15%, 19%, 12% (p=0.79).
  • T1 · PubMedVoroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. 2016, J Diabetes Res 2016:5147468 (PMID 27340676, PMC4908257) — systematic review and meta-analysis, 5 RCTs, 270 patients with type 2 diabetes: silymarin reduced fasting blood glucose (-26.86 mg/dL, 95% CI -35.42 to -18.30) and HbA1c (-1.07, 95% CI -1.73 to -0.40); no effect on lipids. Authors: low quality of evidence and high heterogeneity, "no recommendation can be made."
  • T1 · PubMedGurley BJ, Gardner SF, Hubbard MA, et al. 2004, Clin Pharmacol Ther 76(5):428-440 (PMID 15536458) — 12 healthy volunteers, milk thistle for 28 days, probe cocktail before and after: no significant effect on CYP1A2 (caffeine), CYP2D6 (debrisoquine), CYP2E1 (chlorzoxazone) or CYP3A4 (midazolam); flavonolignan content matched the label. Conclusion: minimal risk for CYP-mediated herb-drug interactions. Confirmed for CYP2D6 in 16 volunteers (Gurley 2008, PMID 18214849).
  • T1 · PubMedKawaguchi-Suzuki M, Frye RF, Zhu HJ, et al. 2014, Drug Metab Dispos 42(10):1611-1616 (PMID 25028567, PMC4164972) — 9 healthy volunteers, standardized milk thistle extract three times daily for 14 days; caffeine, tolbutamide, dextromethorphan and midazolam given together before and after: no significant influence on CYP1A2, CYP2C9, CYP2D6 or CYP3A4/5 activity (peak concentrations and AUCs of the probe drugs assessed).
  • T1 · PubMedGurley BJ, Barone GW, Williams DK, et al. 2006, Drug Metab Dispos 34(1):69-74 (PMID 16221754, PMC1865121) — 16 healthy volunteers, standardized milk thistle 900 mg/day for 14 days, with rifampin and clarithromycin as positive controls: no statistically significant effect on digoxin pharmacokinetics (AUC change approached significance, p=0.06), while rifampin lowered and clarithromycin raised digoxin exposure (p<0.01). Not a potent modulator of P-gp in vivo.
  • T1 · PubMedMills E, Wilson K, Clarke M, et al. 2005, Eur J Clin Pharmacol 61(1):1-7 (PMID 15666173) — randomized controlled trial, 16 healthy participants, milk thistle extract 450 mg three times daily for 4 weeks: indinavir AUC change -4.4% (P=0.78), no significant between-group difference. Meta-analysis of three milk thistle-indinavir trials: pooled mean difference 1% (95% CI -53% to 55%, P=0.97). Conclusion: indinavir levels not significantly reduced.
  • T1 · PubMedHan Y, Guo D, Chen Y, et al. 2009, Eur J Clin Pharmacol 65(6):585-591 (PMID 19221727) — randomized crossover, 12 healthy Chinese men, silymarin 140 mg three times daily for 14 days: losartan AUC increased and the losartan metabolic ratio fell significantly in CYP2C9*1/*1 subjects (not in *1/*3); active metabolite E-3174 AUC decreased in both. + Han Y et al. 2009, Xenobiotica 39(9):694-699 (PMID 19555315) — 18 men: talinolol AUC +36%, oral clearance -23% (p<0.001).
  • T4 · NCCIHNCCIH, "Milk Thistle" fact sheet (nccih.nih.gov/health/milk-thistle, February 2025) — not enough high-quality evidence for definite conclusions on any condition; NCCIH-funded trials in hepatitis C and in NASH showed no benefit from silymarin; may help control blood sugar in type 2 diabetes (few studies). Well tolerated; side effects bloating, nausea, gas. May cause allergic reactions in people allergic to ragweed, chrysanthemum, marigold or daisy. Some products mislabeled or contaminated.
  • T5 · EMA Herbal MonographEMA/HMPC, European Union herbal monograph on Silybum marianum (L.) Gaertn., fructus (EMA/HMPC/294187/2013, adopted 5 June 2018) — TRADITIONAL USE only: "symptomatic relief of digestive disorders, sensation of fullness and indigestion," based exclusively on long-standing use. Contraindicated in Asteraceae allergy. Interactions: "None reported." Adults only; not recommended in pregnancy or lactation; see a doctor if symptoms last over 2 weeks or if jaundice appears.

Minocycline

  • T3 · PubMedNeuvonen 1970, Br Med J 4:532 — iron × tetracyclines (class); + tetracycline HCl FDA label (names zinc + sodium bicarbonate)
  • T6 · FDA PrescribingFDA minocycline HCl prescribing label §7.3

NMN

  • T0 · Preliminary (in vitro / animal)Mills 2016, Cell Metab 24:795 (doi 10.1016/j.cmet.2016.09.013) — 12-month mouse study
  • T1 · PubMedYoshino 2021, Science 372:1224 (doi 10.1126/science.abe9985) — RCT, 25 prediabetic postmenopausal women, 250 mg/d × 10 wk
  • T1 · PubMedYi 2023, GeroScience (doi 10.1007/s11357-022-00705-1) — RCT, 80 adults, 300/600/900 mg/d × 60 d; SPONSOR-RUN (manufacturer)
  • T1 · PubMedFukamizu 2022, Sci Rep 12:14442 (doi 10.1038/s41598-022-18272-y) — RCT, 1250 mg/d × 4 wk; Mitsubishi-funded
  • T1 · PubMedSong 2023, Adv Nutr 14:1416 (doi 10.1016/j.advnut.2023.08.008) — systematic review, 10 human trials
  • T2 · NIH ODSNIH ODS Niacin fact sheet (ods.od.nih.gov/factsheets/Niacin-HealthProfessional)
  • T3 · PubMedOkabe 2022, Front Nutr (doi 10.3389/fnut.2022.868640) — RCT, 250 mg/d × 12 wk; Mitsubishi-funded
  • T3 · PubMedIgarashi 2022, npj Aging (doi 10.1038/s41514-022-00084-z) — RCT, men ≥65, 250 mg/d × 12 wk; n=10/arm at endpoint
  • T3 · PubMedKim 2022, Nutrients 14:755 (doi 10.3390/nu14040755) — RCT, 108 adults ≥65, AM vs PM 250 mg × 12 wk
  • T6 · FDA PrescribingFDA response to docket FDA-2023-P-1867, Sept 29 2025 + NDIN reinstatement letters Dec 2 2025

Omega-3

Omeprazole

  • T1 · PubMedLam 2013, JAMA 310:2435 (doi 10.1001/jama.2013.280490, PMID 24327038) — PPI/H2RA and B12 deficiency, case-control, 25,956 cases vs 184,199 controls
  • T1 · PubMedLam 2017, Gastroenterology 152:821 (PMID 27890768) — PPI and iron deficiency, case-control, 77,046 cases vs 389,314 controls
  • T6 · FDA AdvisoryFDA omeprazole label §5.8 (Hypomagnesemia), codifying the FDA Drug Safety Communication of March 2, 2011
  • T6 · FDA AdvisoryFDA omeprazole label §5.4 (Bone Fracture)

Phenelzine

  • T3 · PubMedVan den Eynde, Gillman & Blackwell 2022, Psychopharmacol Bull 52(2):73 — "The Prescriber's Guide to the MAOI Diet"; + WRHA low-tyramine guideline (Gardner 1996 basis)
  • T6 · FDA PrescribingFDA phenelzine (Nardil) prescribing label — CONTRAINDICATIONS + WARNINGS "Foods and Beverages To Avoid"
  • T6 · FDA PrescribingFDA Nardil label — serotonin-syndrome / contraindicated serotonergic combinations + MAOI washout

PomegranatePunica granatum

  • T0 · Preliminary (in vitro / animal)Hidaka 2005, Drug Metab Dispos (doi 10.1124/dmd.104.002824) — human liver microsomes + rats, carbamazepine CYP3A; companion: Nagata 2007, Drug Metab Dispos 35:302 (PMID 17132763), CYP2C9/tolbutamide in rats
  • T1 · PubMedHanley 2012, Clin Pharmacol Ther 92:651 (doi 10.1038/clpt.2012.170, PMID 23047652) — 4-period crossover, n=12 healthy adults, flurbiprofen 100 mg with pomegranate juice (250 mL) vs pomegranate extract (1 g) vs fluconazole vs control; CYP2C9 probe
  • T1 · PubMedFarkas 2007, J Clin Pharmacol 47:286 (doi 10.1177/0091270006298359, PMID 17322140) — healthy-volunteer PK study, oral + IV midazolam with pomegranate juice vs grapefruit juice; CYP3A probe
  • T1 · PubMedMisaka 2011, Clin Ther 33:246 (doi 10.1016/j.clinthera.2011.02.012, PMID 21497708) — open-label randomized 2-period crossover, healthy Japanese volunteers, 2 weeks of pomegranate juice then single-dose midazolam; CYP3A probe
  • T1 · PubMedAtkin, Sahebkar et al. 2023, Phytother Res 37:4429 (doi 10.1002/ptr.7952, PMID 37461211) — systematic review + meta-analysis, 14 trials, n=573, pomegranate juice and blood pressure
  • T3 · PubMedCase reports: Komperda 2009, Pharmacotherapy 29:1002 (PMID 19637955) + Jarvis 2010, Emerg Med J 27:74 (PMID 20029019), pomegranate juice × warfarin (raised INR); Sorokin 2006, Am J Cardiol (PMID 16923466), pomegranate juice × rosuvastatin + ezetimibe rhabdomyolysis
  • T4 · NCCIHNCCIH, "Pomegranate: Usefulness and Safety" (nccih.nih.gov/health/pomegranate, updated April 2025)

Potassium

  • T2 · NIH ODSNIH ODS Potassium Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/Potassium-HealthProfessional)
  • T2 · NIH ODSNIH ODS Potassium Fact Sheet — Interactions with Medications + impaired-excretion caution

Pravastatin

  • T6 · FDA PrescribingFDA pravastatin (Pravachol) prescribing label §12.3 / Table 4

Red Yeast RiceMonascus purpureus

  • T1 · PubMedGordon 2010, Arch Intern Med 170:1722 (doi 10.1001/archinternmed.2010.382, PMID 20975018) — monacolin variability + citrinin in commercial RYR
  • T1 · PubMedLiu 2006, Chin Med 1:4 (doi 10.1186/1749-8546-1-4) — RYR for lipids, meta-analysis of 93 RCTs, n=9,625
  • T3 · PubMedNIH LiverTox (NBK548168) — Red Yeast Rice; + EFSA ANS Panel 2018, EFSA Journal 16(8):5368 (monacolin K = lovastatin)
  • T6 · FDA AdvisoryFDA position (via NCCIH): red yeast rice with meaningful monacolin K = unapproved new drug; + FDA lovastatin label (the inherited grapefruit/CYP3A4 interaction)

ResveratrolPolygonum cuspidatum

  • T0 · PubMedPacholec 2010, J Biol Chem 285:8340 (PMID 20061378, Pfizer) — biochemistry; counter-argued by Hubbard 2013, Science 339:1216 (Sinclair/Sirtris-aligned)
  • T1 · PubMedLiu 2014, Am J Clin Nutr (doi 10.3945/ajcn.113.082024) — meta-analysis, 11 RCTs, 388 participants
  • T1 · PubMedZhu 2017, Nutr Metab 14:60 (doi 10.1186/s12986-017-0217-z) — meta-analysis, 9 RCTs, 283 T2DM patients
  • T1 · PubMedAkbari 2020, Lipids Health Dis 19:25 (doi 10.1186/s12944-020-1198-x) — meta-analysis, 31 RCTs, 1722 participants
  • T1 · PubMedAkbari 2020, Lipids Health Dis 19:25 (doi 10.1186/s12944-020-1198-x) — meta-analysis, 31 RCTs, 1722 participants
  • T1 · PubMedSemba 2014, JAMA Intern Med 174:1077 (doi 10.1001/jamainternmed.2014.1582) — prospective cohort, 783 adults ≥65, 9–11 yr, urinary resveratrol metabolites
  • T1 · PubMedGliemann 2013, J Physiol 591:5047 (doi 10.1113/jphysiol.2013.258061) — RCT, older men, 250 mg/d during 8 wk exercise training
  • T1 · PubMedYoshino 2012, Cell Metab 16:658 (doi 10.1016/j.cmet.2012.09.015) — RCT, 75 mg/d × 12 wk, nonobese women with normal glucose tolerance
  • T3 · PubMedChow 2010, Cancer Prev Res 3:1168 (PMID 20716633) — human CYP phenotyping, n=40, 1 g/d × 4 wk, probe-drug cocktail
  • T3 · PubMedWalle 2004, Drug Metab Dispos 32:1377 (doi 10.1124/dmd.104.000885) — 14C PK, 25 mg oral, 6 volunteers; corroborated by Boocock 2007 (PMID 17548692, up to 5 g)
  • T3 · PubMedla Porte 2010, Clin Pharmacokinet 49:449 (doi 10.2165/11531820-000000000-00000) — food-effect PK, 2000 mg BID

RhodiolaRhodiola rosea

  • T0 · Preliminary (in vitro / animal)Hellum BH, Tosse A, Hoybakk K, Thomsen M, Rohloff J, Nilsen OG. 2010, Planta Med 76(4):331-338 (PMID 19790032) — in vitro: ethanol extracts of six R. rosea clones tested on cDNA-expressed CYP3A4 and on P-glycoprotein in Caco-2 cells. All clones inhibited both: IC50 1.7-3.1 microg/mL (CYP3A4) and 16.7-51.7 microg/mL (P-gp). Inhibition did not correlate with levels of the presumed active constituents.
  • T0 · PubMedvan Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K. 2009, J Ethnopharmacol 122(2):397-401 (PMID 19168123) — in vitro microtitre bioassay: R. rosea root methanol extract inhibited MAO-A 92.5% and MAO-B 81.8% at 100 microg/mL; water extract 84.3% and 88.9%. Rosiridin was the most active isolated compound (MAO-B inhibition over 80% at 10^-5 M, pIC50 5.38).
  • T1 · PubMedThu OK, Spigset O, Nilsen OG, Hellum B. 2016, Eur J Clin Pharmacol 72:295-300 (doi 10.1007/s00228-015-1988-7) — randomized crossover CYP "cocktail" study, n=13 healthy volunteers, 14 days of a commercial R. rosea product (Arctic Root): losartan metabolic ratio (EXP-3174/losartan) fell 21% (p=0.023), i.e. reduced CYP2C9 activity, stronger in CYP2C9 extensive metabolizers. No significant effect on CYP1A2, CYP2C19, CYP2D6, or CYP3A4.
  • T1 · PubMedIshaque S, Shamseer L, Bukutu C, Vohra S. 2012, BMC Complement Altern Med 12:70 (PMID 22643043, PMC3541197) — systematic review, 11 trials (10 RCTs, 1 controlled trial). Physical fatigue: 2 of 6 trials in healthy populations reported benefit. Mental fatigue: 3 of 5 RCTs reported benefit. All included studies had a high risk of bias or reporting flaws. Authors: "Research regarding R. rosea efficacy is contradictory."
  • T1 · PubMedMao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD. 2015, Phytomedicine 22(3):394-399 (PMID 25837277, PMC4385215) — phase II RCT, n=57, mild-to-moderate major depressive disorder, 12 wk, standardized R. rosea extract vs sertraline vs placebo. HAM-D change: sertraline -8.2, R. rosea -5.1, placebo -4.6 (between-group p=0.79, not significant). Adverse events: sertraline 63.2%, R. rosea 30.0%, placebo 16.7% (p=0.012).
  • T3 · PubMedBooker A, Jalil B, Frommenwiler D, Reich E, Zhai L, Kulic Z, Heinrich M. 2016, Phytomedicine 23(7):754-762 (PMID 26626192) — HPTLC, MS and 1H-NMR analysis of about 40 commercial products: approximately one fifth of products claiming to be R. rosea contained no rosavin (the marker that distinguishes R. rosea); approximately 80% of the rest had less rosavin than registered products. Adulteration with other Rhodiola species "appears to be commonplace."
  • T3 · PubMedManiscalco I, Toffol E, Giupponi G, et al. 2015, Neuropsychiatrie 29:36-38 (doi 10.1007/s40211-014-0124-8) — single case report: a 68-year-old woman with recurrent moderate depression on paroxetine who self-medicated with Rhodiola rosea developed vegetative symptoms, restlessness and trembling, interpreted by the authors as a serotonergic syndrome; they assume both pharmacokinetic and pharmacodynamic interactions.
  • T4 · NCCIHNCCIH, "Rhodiola: Usefulness and Safety" (nccih.nih.gov/health/rhodiola, updated April 2025) — "There isn't enough reliable evidence to determine whether rhodiola or its components are useful" for any health purpose; most human research is of low-to-moderate quality. "Possibly safe for up to 12 weeks." Side effects: dizziness, headache, insomnia, dry mouth or excessive saliva. Little is known about safety in pregnancy or breastfeeding. Interactions with losartan have been reported.
  • T5 · EMA Herbal MonographEMA/HMPC, European Union herbal monograph on Rhodiola rosea L., rhizoma et radix, Revision 1 (EMA/HMPC/24177/2023; first published Aug 2023, opinion and assessment report May 2024) — traditional herbal medicinal product "for temporary relief of symptoms of stress, such as fatigue and sensation of weakness." Basis: long-standing traditional use; clinical evidence judged insufficient. Adults over 18 only; not for more than two weeks without medical advice.

Rosuvastatin

  • T6 · FDA PrescribingFDA rosuvastatin (Crestor) prescribing label §12.3

Saw PalmettoSerenoa repens

  • T0 · PubMedBayne CW et al. 1999, Prostate (PMID 10420151) — in vitro coculture model of BPH: the hexane extract Permixon at 10 micrograms/mL (the calculated plasma concentration at the recommended dose) inhibited both type I and type II 5-alpha-reductase isoenzymes without changing PSA secretion by epithelial cells. Confirmed in prostate cancer cell lines: Habib FK et al. 2005, Int J Cancer (PMID 15543614) — 5-alpha-reductase inhibited, androgen receptor signaling and PSA expression unaffected.
  • T1 · Cochrane ReviewFranco JVA et al. 2023, Cochrane Database Syst Rev (PMID 37345871) — 27 placebo-controlled studies, 4656 men. Serenoa repens alone, low-risk-of-bias studies: IPSS mean difference -0.90 (95% CI -1.74 to -0.07; 9 studies, 1681 men; scale 0-35) at 3-6 months and 0.07 (-0.75 to 0.88) at 12-17 months; adverse events RR 1.01 (0.77-1.31). High-certainty evidence. Conclusion: "little to no benefits for men with lower urinary tract symptoms due to benign prostatic enlargement."
  • T1 · PubMedBarry MJ et al. 2011, JAMA (PMID 21954478) — CAMUS double-blind RCT, 369 men aged 45+, saw palmetto extract escalated from 320 to 640 to 960 mg/day over 72 weeks vs placebo: AUA symptom score fell 2.20 points with saw palmetto and 2.99 with placebo (difference 0.79 favoring placebo; 1-sided P=.91); no benefit on any secondary outcome. Earlier: Bent S et al. 2006, N Engl J Med (PMID 16467543) — STEP, 225 men, 160 mg twice daily for 1 year: no difference (0.04 point).
  • T1 · PubMedAndriole GL et al. 2013, J Urol, Feb (PMID 23253958) — CAMUS trial analysis, 369 men, saw palmetto 320, 640 then 960 mg/day over 72 weeks vs placebo: mean PSA change 0.23 ng/mL with saw palmetto vs 0.16 ng/mL with placebo (p=0.50); no differential effect when stratified by baseline PSA. Conclusion: saw palmetto "does not affect serum prostate specific antigen more than placebo, even at relatively high doses."
  • T1 · PubMedEvron E et al. 2020, Skin Appendage Disord, Nov (PMID 33313047) — systematic review: 5 randomized trials and 2 prospective cohort studies of oral and topical supplements CONTAINING saw palmetto (100-320 mg) in androgenetic alopecia and telogen effluvium reported positive effects (e.g. 27% improvement in total hair count; increased hair density in 83.3% of patients). Well tolerated. Authors: "robust high-quality data are lacking"; trials isolating saw palmetto's own contribution are needed.
  • T1 · PubMedAgbabiaka TB et al. 2009, Drug Saf (PMID 19591529) — systematic review of adverse events with single-ingredient Serenoa repens, 40 articles (26 RCTs): events "mild and similar to those with placebo"; most frequent abdominal pain, diarrhoea, nausea, fatigue, headache, decreased libido, rhinitis; no drug interactions reported. + Avins AL et al. 2013, J Urol, Apr (PMID 23063633) — CAMUS: no evidence of toxicity at up to 3 times the usual dose over 18 months.
  • T1 · PubMedMarkowitz JS et al. 2003, Clin Pharmacol Ther, Dec (PMID 14663456) — 12 healthy volunteers, saw palmetto 320 mg daily for 14 days: alprazolam AUC 476 vs 479 h·ng/mL (P=.923) and half-life unchanged (CYP3A4); dextromethorphan ratio unchanged (CYP2D6). + Gurley BJ et al. 2004, Clin Pharmacol Ther 76(5):428-440 (PMID 15536458) — 12 volunteers, 28 days: no significant effect on CYP1A2, CYP2D6, CYP2E1 or CYP3A4.
  • T3 · PubMedCheema P et al. 2001, J Intern Med, Aug (PMID 11489067) — case report and literature review: severe intraoperative haemorrhage in a patient taking saw palmetto; his prolonged bleeding time normalized a few days after he stopped the herb.
  • T3 · PubMedNIH LiverTox, "Saw Palmetto" (NBK548378, updated April 2, 2020) — chronic use not linked to serum enzyme elevations, and prospective trials found little or no evidence of liver injury; rare case reports of clinically apparent liver injury, onset within 1 to 2 weeks, hepatocellular pattern, resolving in 1 to 3 months, some with other possible causes. Likelihood score D (possible, rare cause of clinically apparent liver injury). No fatalities, transplants or chronic injury.
  • T4 · NCCIHNCCIH, "Saw Palmetto" (nccih.nih.gov/health/saw-palmetto, April 2025) — "probably not helpful" for urinary symptoms of an enlarged prostate; two NIH-funded trials, at standard and up to three times the usual dose, showed no improvement; hexane-extracted products did not differ from others. Hair loss: evidence "too limited to allow conclusions." Does not appear to affect PSA. Well tolerated, used in studies for up to 3 years; side effects digestive symptoms, dizziness, headache.
  • T5 · EMA Herbal MonographEMA/HMPC, European Union herbal monograph on Serenoa repens (W. Bartram) Small, fructus (EMA/HMPC/280079/2013, final, adopted 24 Nov 2015) — well-established use, hexane soft extract: "symptomatic treatment of benign prostatic hyperplasia." Traditional use, ethanol extract: relief of lower urinary tract symptoms after a doctor has excluded serious conditions. 320 mg/day. Interactions: "A few cases of suspected interactions with warfarin have been reported." No relevant use in women or under 18.

Selegiline

  • T3 · PubMedSelegiline MAO-B selectivity — oral low-dose (Parkinson's, ≤10 mg) MAO-B-selective; selectivity lost at higher/antidepressant doses
  • T6 · FDA PrescribingFDA selegiline transdermal (Emsam) prescribing label §2.1 / §2.3 / §7.2 / §12.2

Simvastatin

  • T1 · PubMedBailey 2013, CMAJ 185:309 (doi 10.1503/cmaj.120951, PMID 23184849) — grapefruit–medication interactions mechanism review
  • T1 · PubMedQu 2018, Eur J Med Res 23:57 (doi 10.1186/s40001-018-0353-6) — statins and circulating CoQ10, meta-analysis of RCTs
  • T6 · FDA PrescribingFDA simvastatin (Zocor) prescribing label §5.1 / §7.1 / Table 2 / Table 4

Spironolactone

  • T6 · FDA PrescribingFDA spironolactone label §7.1 — the potassium-raising co-agents (ACE/ARB/NSAID/trimethoprim/heparin) + salt substitutes
  • T6 · FDA PrescribingFDA spironolactone prescribing label §4 / §5.1 / §7.1 / §17

St John's WortHypericum perforatum

  • T0 · Preliminary (in vitro / animal)Moore LB, Goodwin B, Jones SA, et al. 2000, Proc Natl Acad Sci USA 97(13):7500-7502 (PMID 10852961, PMC16574) — in vitro: hyperforin, a constituent of St. John's wort, is a potent ligand (Ki 27 nM) for the pregnane X receptor (PXR), the nuclear receptor that regulates CYP3A4 expression; treating primary human hepatocytes with hypericum extract or hyperforin markedly induced CYP3A4.
  • T1 · PubMedLinde K, Berner MM, Kriston L. 2008, Cochrane Database Syst Rev (4):CD000448 (PMID 18843608, PMC7032678) — 29 randomized double-blind trials, 5489 patients with major depression. Response vs placebo: RR 1.28 (95% CI 1.10-1.49) in 9 larger trials, 1.87 (1.22-2.87) in 9 smaller. vs SSRIs RR 1.00 (0.90-1.11); vs tricyclics 1.02 (0.90-1.15). Fewer dropouts for adverse effects than SSRIs (OR 0.53, 0.34-0.83). Trials from German-speaking countries more favorable.
  • T1 · PubMedHypericum Depression Trial Study Group (Davidson JRT et al.). 2002, JAMA 287(14):1807-1814 (PMID 11939866) — double-blind RCT, 340 US outpatients with major depression (HAM-D 20 or more), hypericum extract LI-160 900-1500 mg/day vs sertraline vs placebo, 8 weeks: HAM-D change -8.68 hypericum vs -9.20 placebo (P=.59), -10.53 sertraline (P=.18). Full response 23.9% vs 31.9% placebo vs 24.8% sertraline. Neither active arm beat placebo on primary outcomes.
  • T1 · PubMedMarkowitz JS, Donovan JL, DeVane CL, et al. 2003, JAMA 290(11):1500-1504 (PMID 13129991) — open-label fixed-order crossover, 12 healthy volunteers, St. John's wort 300 mg three times daily for 14 days: alprazolam AUC decreased 2-fold and clearance increased 2-fold (both P<.001); half-life 12.4 h to 6.0 h. Dextromethorphan/dextrorphan ratio (CYP2D6) unchanged (P=.26).
  • T1 · PubMedMueller SC, Majcher-Peszynska J, Uehleke B, et al. 2006, Eur J Clin Pharmacol 62(1):29-36 (PMID 16341856) — 42 healthy men randomized to six St. John's wort products for 14 days: midazolam AUC fell 79.4% with extract LI 160 (hyperforin 41 mg/day), 47.9% with powder tablets (12 mg/day), 21.1% with tablets nearly devoid of hyperforin (0.13 mg/day); decrease correlated with hyperforin dose (r=-0.765, p<0.001), not hypericin. Follow-up (Mueller 2009, PMID 18762932): low-hyperforin powder, -11.3%.
  • T1 · PubMedPiscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000, Lancet 355(9203):547-548 (PMID 10683007) — healthy volunteers: St. John's wort reduced the AUC of the HIV-1 protease inhibitor indinavir by a mean of 57% (SD 19) and the extrapolated 8-hour trough by 81% (SD 16). Authors: a reduction of this magnitude could lead to drug resistance and treatment failure.
  • T1 · PubMedBauer S, Stormer E, Johne A, et al. 2003, Br J Clin Pharmacol 55(2):203-211 (PMID 12580993, PMC1894728) — open-label, 11 renal transplant patients, St. John's wort extract 600 mg/day for 14 days added to cyclosporine: dose-corrected cyclosporine AUC -46%, Cmax -42%, trough -41%; doses raised from median 2.7 to 4.2 mg/kg/day, first adjustment needed after 3 days. Clinical consequence: Ruschitzka F et al. 2000, Lancet 355:548-549 (PMID 10683008) — acute rejection in two heart transplant patients.
  • T1 · PubMedJohne A, Brockmoller J, Bauer S, et al. 1999, Clin Pharmacol Ther 66(4):338-345 (PMID 10546917) — single-blind placebo-controlled parallel study, healthy volunteers at digoxin steady state (0.25 mg/day), hypericum extract LI160 900 mg/day (n=13) vs placebo (n=12) for 10 days: no change after the first dose; after 10 days digoxin AUC -25% (P=.0035), trough -33%, Cmax -26%. Effect grew through day 10. Proposed mechanism: induction of P-glycoprotein.
  • T1 · PubMedHall SD, Wang Z, Huang SM, et al. 2003, Clin Pharmacol Ther 74(6):525-535 (PMID 14663455) — 12 women on ethinyl estradiol/norethindrone, St. John's wort 900 mg/day for 2 cycles: norethindrone oral clearance up (P=.042), ethinyl estradiol half-life 23.4 h to 12.2 h; breakthrough bleeding 7 of 12 vs 2 of 12. + Murphy PA et al. 2005, Contraception 71(6):402-408 (PMID 15914127) — 16 women: 13-15% lower contraceptive exposure, more breakthrough bleeding, follicle growth and probable ovulation.
  • T1 · PubMedJiang X, Williams KM, Liauw WS, et al. 2004, Br J Clin Pharmacol 57(5):592-599 (PMID 15089812, PMC1884493) — open-label randomized three-way crossover, 12 healthy men, single 25 mg warfarin dose alone or after 14 days of St. John's wort: apparent clearance ratio 1.29 (90% CI 1.16-1.46) for S-warfarin and 1.23 (1.11-1.37) for R-warfarin; INR AUC ratio 0.79 (0.70-0.95). St. John's wort alone did not affect INR or platelet aggregation.
  • T1 · PubMedMathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. 2002, J Natl Cancer Inst 94(16):1247-1249 (PMID 12189228) — unblinded randomized crossover, 5 cancer patients given irinotecan 350 mg/m2 with and without St. John's wort 900 mg/day for 18 days: plasma levels of the active metabolite SN-38 decreased 42% (95% CI 14-70%, P=.033); myelosuppression was substantially worse without St. John's wort. Authors: patients on irinotecan should refrain from St. John's wort.
  • T3 · PubMedLantz MS, Buchalter E, Giambanco V. 1999, J Geriatr Psychiatry Neurol 12(1):7-10 (PMID 10447148) — case series: five elderly patients who combined prescription antidepressants with St. John's wort developed clinically diagnosed central serotonergic syndrome.
  • T4 · NCCIHNCCIH, "St. John's Wort" fact sheet (nccih.nih.gov/health/st-johns-wort, May 2025) — appears more effective than placebo and about as effective as standard antidepressants for mild or moderate depression; uncertain for severe depression or beyond 12 weeks. Can interact in dangerous, sometimes life-threatening ways: weakens some antidepressants, birth control pills, cyclosporine, seizure drugs, digoxin, HIV drugs, cancer drugs, warfarin, some statins. May be unsafe in pregnancy.
  • T5 · EMA Herbal MonographEMA/HMPC, European Union herbal monograph on Hypericum perforatum L., herba, Revision 1 (EMA/HMPC/7695/2021, adopted 23 Nov 2022) — well-established use: "treatment of mild to moderate depressive episodes"; traditional use: temporary mental exhaustion, minor skin inflammation and wounds, mild GI discomfort, nervous restlessness. Above 1 mg hyperforin/day: contraindicated with coumarin anticoagulants, cyclosporine, tacrolimus, sirolimus, everolimus, protease inhibitors, irinotecan, imatinib.
  • T6 · FDA PrescribingFDA, "Examples of Drugs that Interact with CYP Enzymes and Transporter Systems" (fda.gov, page modified 05/29/2026) — St. John's wort listed as a strong CYP3A inducer (strong = 80% or greater decrease in AUC of a sensitive substrate), footnote: "The effect of St. John's wort varies widely and is preparation dependent." + PAXLOVID prescribing information (Rev. 05/2023) sections 4 and 7.3: St. John's Wort contraindicated, potential loss of virologic response and possible resistance.

SulforaphaneBrassica oleracea

  • T1 · PubMedSingh K et al. 2014, PNAS 111(43):15550-15555 (PMID 25313065, PMC4217462) — double-blind placebo-controlled RCT, 44 young men aged 13-27 with moderate-severe ASD (29 sulforaphane / 15 placebo), broccoli-sprout-derived sulforaphane 50-150 umol/day x 18 wk: Aberrant Behavior Checklist improved 34% (P<0.001) and Social Responsiveness Scale 17% (P=0.017) vs placebo; scores rose back toward baseline after stopping.
  • T1 · PubMedEgner PA et al. 2014, Cancer Prev Res 7(8):813-823 (PMID 24913818) — RCT, 291 adults, Qidong China, broccoli-sprout beverage (600 umol glucoraphanin + 40 umol sulforaphane/day) x 12 wk: urinary excretion of the benzene mercapturic acid rose 61% and the acrolein conjugate 23% vs placebo (P<=0.01); crotonaldehyde not significant.
  • T1 · PubMedFahey JW et al. 2015, PLoS ONE 10(11):e0140963 (PMID 26524341) — human bioavailability: glucoraphanin preparations WITHOUT active myrosinase yielded only ~10% of dose as urinary sulforaphane metabolites (gut-microbe dependent); WITH active myrosinase (fresh sprouts/seed powder) ~34-40% (3-4x more); pre-hydrolyzed ~41%. A commercial broccoli-seed supplement without myrosinase delivered only ~10.4%. Person-to-person conversion ranged 1-40%.

TB-500

  • T0 · Preliminary (in vitro / animal)Ho 2012, J Chromatogr A 1265:57 (doi 10.1016/j.chroma.2012.09.043, PMID 23084823) — Hong Kong Jockey Club racing laboratory: identification of TB-500 and metabolites in horses after administration; companion identity paper Esposito 2012 (doi 10.1002/dta.1402, PMID 22962027)
  • T0 · Preliminary (in vitro / animal)Rahaman 2024, J Chromatogr B 1235:124033 (doi 10.1016/j.jchromb.2024.124033, PMID 38382158) — KIST Doping Control Center: TB-500 metabolism in rats + human serum in vitro, with fibroblast wound-healing assay
  • T0 · Preliminary (in vitro / animal)Safer 1991, J Biol Chem 266:4029 (PMID 1999398) — thymosin β4 identified as the major G-actin-sequestering peptide
  • T0 · Preliminary (in vitro / animal)Bock-Marquette 2004, Nature 432:466 (doi 10.1038/nature03000, PMID 15565145) — mouse coronary ligation, full-length Tβ4; companion Smart 2007, Nature 445:177 (PMID 17108969) — epicardial progenitor mobilization
  • T0 · Preliminary (in vitro / animal)Malinda 1999, J Invest Dermatol 113:364 (doi 10.1046/j.1523-1747.1999.00708.x, PMID 10469335) — rat full-thickness wounds, topical or i.p. full-length Tβ4
  • T1 · PubMedGuarnera 2010, Ann N Y Acad Sci 1194:207 (doi 10.1111/j.1749-6632.2010.05490.x, PMID 20536470) — Phase 2 double-blind placebo-controlled dose-escalation, TOPICAL full-length thymosin β4, n=73 venous stasis ulcers
  • T1.5 · Peptide Clinical PracticeMendias & Awan 2026, Sports Med 56:1921 (doi 10.1007/s40279-026-02437-0, PMID 41966639) — clinical review: approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
  • T3 · PubMedSosne 2015, Cornea 34:491 (doi 10.1097/ICO.0000000000000379, PMID 25826322; NCT01393132) — Phase 2 double-masked RCT, RGN-259 0.1% thymosin β4 EYE DROPS, n=9 severe dry eye
  • T3 · PubMedRuff 2010, Ann N Y Acad Sci 1194:223 (doi 10.1111/j.1749-6632.2010.05474.x, PMID 20536472) — randomized placebo-controlled Phase 1, IV full-length thymosin β4, 40 healthy subjects, single then 14 daily doses of 42–1260 mg
  • T6 · FDA AdvisoryFDA 503A actions on "Thymosin Beta-4, Fragment (LKKTETQ)": Category 2 placement (significant safety risk) Sept 29 2023, same batch as BPC-157 → nomination withdrawn (FDA "may present significant safety risks" page) → PCAC July 23–24 2026 briefing (fda.gov/media/193349): proposed NOT adding TB-500 free base or acetate to the 503A Bulks List

Tranylcypromine

  • T6 · FDA PrescribingFDA tranylcypromine (Parnate) prescribing label §5.2 + Table 5 (tyramine foods)
  • T6 · FDA PrescribingFDA Parnate label §7.2 (mechanism) + boxed warning (serotonergic + tyramine)

Urolithin A

  • T1 · PubMedAndreux PA et al. 2019, Nat Metab 1(6):595-603 (PMID 32694802) — first-in-human trial, healthy sedentary elderly, single + 4-week repeated oral dosing (incl. 500 and 1000 mg). Primary outcome SAFETY: favourable profile. UA bioavailable in plasma at all doses. At 500/1000 mg x 4 wk: modulated plasma acylcarnitines and skeletal-muscle mitochondrial gene expression — a molecular signature of improved mitochondrial/cellular health.
  • T1 · PubMedLiu S et al. 2022, JAMA Netw Open 5(1):e2144279 (PMID 35050355, PMC8777576, NCT03283462) — double-blind RCT, 66 adults aged 65-90, 1000 mg UA/day vs placebo x 4 mo. PRIMARY endpoints (6-min walk distance; maximal muscle ATP production) NOT significant vs placebo. Secondary: significantly improved muscle endurance at 2 mo; at 4 mo decreased plasma acylcarnitines, ceramides, and C-reactive protein. Safe, well tolerated, no AE difference.
  • T1 · PubMedSingh A et al. 2022, Cell Rep Med 3(5):100633 (PMID 35584623, PMC9133463, NCT03464500) — randomized placebo-controlled trial, middle-aged adults, two doses x 4 mo: ~12% increase in muscle strength; clinically meaningful gains in VO2 peak and 6-min walk; PRIMARY endpoint (peak power output) NOT significant. Lower plasma acylcarnitines and C-reactive protein; increased skeletal-muscle mitophagy/mitochondrial protein expression.
  • T6 · FDA AdvisoryFDA GRAS Notice GRN 791 (2018) — synthetic urolithin A (Amazentis): FDA responded with a "no questions" letter to the GRAS determination for use of urolithin A in specified foods/beverages. A food-safety (GRAS) endorsement, NOT a therapeutic approval or an efficacy judgment.

ValerianValeriana officinalis

  • T0 · Preliminary (in vitro / animal)Khom S, Baburin I, Timin E, et al. 2007, Neuropharmacology 53(1):178-187 (PMID 17585957) — in vitro, GABA-A receptors expressed in Xenopus oocytes: valerenic acid, a valerian constituent, is a subunit-specific allosteric modulator that enhances GABA-induced chloride currents only at receptors containing beta2 or beta3 subunits; not blocked by flumazenil; inhibits at 100 microM or more. Extract activity tracks valerenic acid content (Trauner 2008, PMID 18095218).
  • T1 · PubMedBent S, Padula A, Moore D, Patterson M, Mehling W. 2006, Am J Med 119(12):1005-1012 (PMID 17145239, PMC4394901) — meta-analysis, 16 randomized placebo-controlled trials, 1093 patients; most had significant methodologic problems, and doses, preparations and durations varied. Six studies reported sleep quality as improved or not: relative risk of improved sleep 1.8 (95% CI 1.2-2.9), with evidence of publication bias. Authors: valerian "might improve sleep quality without producing side effects."
  • T1 · PubMedFernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, et al. 2010, Sleep Med 11(6):505-511 (PMID 20347389) — meta-analysis, 18 randomized placebo-controlled trials (8 scored 5 on the Jadad scale): time to fall asleep, mean difference 0.70 min (95% CI -3.44 to 4.83); sleep quality on visual analogue scales, SMD -0.02 (-0.35 to 0.31); yes/no sleep-quality improvement RR 1.37 (1.05-1.78). Effectiveness "has not been demonstrated with quantitative or objective measurements."
  • T1 · PubMedTaibi DM, Landis CA, Petry H, Vitiello MV. 2007, Sleep Med Rev 11(3):209-230 (PMID 17517355) — systematic review, 37 studies (29 controlled trials, 8 open-label safety studies): most found no significant difference between valerian and placebo in healthy people or in people with sleep disturbance or insomnia; none of the most recent, most rigorous studies found a significant effect. Conclusion: safe, with only rare adverse events, but evidence "does not support the clinical efficacy."
  • T1 · PubMedShinjyo N, Waddell G, Green J. 2020, J Evid Based Integr Med 25:2515690X20967323 (PMID 33086877, PMC7585905) — systematic review of 60 studies (n=6,894), with meta-analyses of subjective sleep quality (10 studies, n=1,065) and anxiety (8 studies, n=535). Authors attribute inconsistent outcomes to variable quality of herbal extracts and suggest more reliable effects from whole root/rhizome. No severe adverse events in subjects aged 7 to 80.
  • T1 · Cochrane ReviewMiyasaka LS, Atallah AN, Soares BG. 2006, Cochrane Database Syst Rev (4):CD004515 (PMID 17054208) — only one eligible RCT: 36 patients with generalised anxiety disorder, 4 weeks, valerian vs diazepam vs placebo. No significant difference between valerian and placebo on HAM-A total, somatic or psychic scores. No differences in side effects or dropouts. Authors: "insufficient evidence to draw any conclusions about the efficacy or safety of valerian" for anxiety disorders.
  • T1 · PubMedGlass JR, Sproule BA, Herrmann N, Streiner D, Busto UE. 2003, J Clin Psychopharmacol 23(3):260-268 (PMID 12826988) — double-blind crossover, 14 healthy adults aged 65-89, single doses: valerian 400 and 800 mg did not differ from placebo on sedation or psychomotor tests, while temazepam and diphenhydramine caused sedation and impairment. + Gutierrez S et al. 2004, Pharmacol Biochem Behav 78(1):57-64 (PMID 15159134) — 10 young adults: valerian 600-1800 mg, no effect; diazepam 10 mg impaired.
  • T1 · PubMedDonovan JL, DeVane CL, Chavin KD, et al. 2004, Drug Metab Dispos 32(12):1333-1336 (PMID 15328251) — 12 healthy volunteers, valerian 1000 mg nightly for 14 days: alprazolam Cmax rose from 25 to 31 ng/mL (p<0.05) with no significant change in AUC or half-life; dextromethorphan ratio (CYP2D6) unchanged. + Gurley BJ et al. 2005, Clin Pharmacol Ther 77(5):415-426 (PMID 15900287) — 12 volunteers, 28 days: no significant change in CYP1A2, CYP2D6, CYP2E1 or CYP3A4/5 phenotypes.
  • T1.5 · PubMedSateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. 2017, J Clin Sleep Med 13(2):307-349 (PMID 27998379, PMC5263087) — American Academy of Sleep Medicine clinical practice guideline, GRADE method: "We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. (WEAK)." The same guideline suggests against melatonin, diphenhydramine, tryptophan and trazodone.
  • T3 · PubMedNIH LiverTox, "Valerian" (NBK548255, updated April 5, 2020) — implicated in a small number of cases of clinically apparent liver injury, usually in combination with other botanicals such as skullcap or black cohosh; latency 3 to 12 weeks; hepatocellular or mixed pattern; usually mild to moderate with recovery within 2 to 4 months of stopping. Likelihood score C (probable rare cause of clinically apparent liver injury). No convincing case of acute liver failure.
  • T4 · NCCIHNCCIH, "Valerian" (nccih.nih.gov/health/valerian, May 2025) — evidence for sleep problems is inconsistent; notes the AASM 2017 guideline recommends against it for chronic insomnia; not enough evidence for anxiety, depression, stress or menopause symptoms. Generally safe short term, 300 to 600 mg daily for up to 6 weeks; long-term safety unknown. Side effects: headache, stomach upset, mental dullness, excitability, uneasiness, vivid dreams. Should not be taken with alcohol or sedatives.
  • T5 · EMA Herbal MonographEMA/HMPC, European Union herbal monograph on Valeriana officinalis L., radix (EMA/HMPC/150848/2015 Corr.1, adopted 2 Feb 2016) — well-established use, ethanol dry extract only: "relief of mild nervous tension and sleep disorders"; traditional use, other preparations: mild symptoms of mental stress and to aid sleep. Gradual onset, unsuitable for acute treatment; continued use over 2-4 weeks recommended. Interactions: "None reported." "May impair ability to drive and use machines." Not under 12.

Vitamin D3+K2

  • T0 · Preliminary (in vitro / animal)Luo 1997, Nature 386:78 (doi 10.1038/386078a0, PMID 9052783) — MGP-knockout mice; mechanism context: van Ballegooijen 2017 review (PMID 29138634)
  • T1 · PubMedManson 2019 (VITAL, vitamin D arm), N Engl J Med 380:33 (doi 10.1056/NEJMoa1809944, PMID 30415629) — RCT, n=25871, D3 2000 IU/d, median 5.3 y, NIH-funded
  • T1 · PubMedLeBoff 2022 (VITAL fracture ancillary), N Engl J Med 387:299 (doi 10.1056/NEJMoa2202106, PMID 35939577) — n=25871, 1991 fractures
  • T1 · PubMedNeale 2022 (D-Health), Lancet Diabetes Endocrinol 10:120 (doi 10.1016/S2213-8587(21)00345-4, PMID 35026158) — RCT, n=21315 Australians ≥60, 60000 IU MONTHLY × 5 y
  • T1 · PubMedJolliffe 2021, Lancet Diabetes Endocrinol 9:276 (doi 10.1016/S2213-8587(21)00051-6, PMID 33798465) — updated meta-analysis, 43 trials, n=48488, vitamin D and acute respiratory infections
  • T1 · PubMedDiederichsen 2022 (AVADEC), Circulation 145:1387 (doi 10.1161/CIRCULATIONAHA.121.057008, PMID 35465686) — RCT, n=365 men with aortic valve calcification, MK-7 720 µg/d + vitamin D 25 µg/d × 24 mo
  • T1 · PubMedDai Q et al. 2018, Am J Clin Nutr 108(6):1249-1258 (PMID 30541089; NCT03265483) — 180 adults aged 40-85, NCI-funded study nested in a double-blind randomized trial of magnesium vs placebo (doses customized to dietary intake). Magnesium raised 25(OH)D3 when baseline 25(OH)D was close to 30 ng/mL and lowered it when baseline was higher (about 30 to 50 ng/mL). Deng X et al. 2013, BMC Med 11:187 (PMID 23981518) — NHANES: higher magnesium intake associated with lower risk of vitamin D deficiency.
  • T1.5 · PubMedDemay 2024, Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 109:1907 (doi 10.1210/clinem/dgae290, PMID 38828931) — vitamin D for disease prevention; companion: USPSTF 2021 (PMID 33847711, I-statement on screening)
  • T2 · NIH ODSNIH ODS Vitamin D Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/VitaminD-HealthProfessional)
  • T2 · NIH ODSNIH ODS Vitamin K Fact Sheet for Health Professionals (ods.od.nih.gov/factsheets/VitaminK-HealthProfessional)
  • T3 · PubMedSchurgers 2007, Blood 109:3279 (doi 10.1182/blood-2006-08-040709, PMID 17158229) — K1 vs natto-derived MK-7 pharmacokinetics (VitaK group; one NattoPharma-affiliated co-author); companion: Sato 2012 (PMID 23140417 — nutritional-dose MK-4 undetectable in serum)
  • T3 · PubMedKnapen 2013, Osteoporos Int 24:2499 (doi 10.1007/s00198-013-2325-6, PMID 23525894) — RCT, n=244 healthy postmenopausal women, MK-7 180 µg/d × 3 y; NattoPharma sponsorship (verified via trade press; VitaK authors)
  • T3 · PubMedCockayne 2006, Arch Intern Med 166:1256 (doi 10.1001/archinte.166.12.1256, PMID 16801507) — meta-analysis of 7 Japanese MK-4 45 mg/d fracture trials — READ WITH its 2018 correction (JAMA Intern Med 178:875 erratum + Grey/Avenell/Bolland letter)
  • T3 · PubMedFatemi S et al. 1991, J Clin Endocrinol Metab 73(5):1067-72 (PMID 1939521) — 26 normal subjects on a 3-week low-magnesium diet (under 1 meq/day): serum magnesium fell from 0.80 to 0.61 mmol/L, serum 1,25-dihydroxyvitamin D fell from 55 ± 4 to 43 ± 3 pmol/L (P<0.05), and PTH secretion was impaired. Rude RK et al. 1985, J Clin Endocrinol Metab 61(5):933-40 (PMID 3840173) — 23 hypocalcemic magnesium-deficient patients: 16 had low 1,25-(OH)2D; 25-OHD did not change with magnesium therapy.
  • T6 · FDA PrescribingFDA warfarin (Coumadin) prescribing information, §7.5 drug–food interactions; plus 21 CFR 101.72 (authorized health claim: calcium, vitamin D, and osteoporosis)

Warfarin

  • T1 · PubMedSconce 2007, Blood 109:2419 (doi 10.1182/blood-2006-09-049262) — double-blind RCT, 70 unstable AF patients, 150 µg/d oral vitamin K vs placebo, 6 months
  • T1 · PubMedMohammed Abdul 2008, Br J Pharmacol 154:1691 (doi 10.1038/bjp.2008.210, PMID 18516070) — crossover, cranberry AND garlic × warfarin; + Ansell 2009, J Clin Pharmacol 49:824 (cranberry juice RCT, n=30)
  • T3 · PubMedSconce 2005, Thromb Haemost 93:872 (doi 10.1160/TH04-12-0773) — 26 unstable vs 26 stable warfarin patients, food diaries
  • T3 · PubMedJiang 2005, Br J Clin Pharmacol 59:425 (PMID 15801942) — ginkgo + ginger × warfarin; + Nutrients 2016 fish-oil cohort (n=573)
  • T6 · FDA PrescribingFDA warfarin (Coumadin) prescribing label §7.5 (Botanical/Foods) + §17 Medication Guide
  • T6 · FDA PrescribingFDA warfarin label §7.5 — St John's Wort (CYP/VKA inducer context) + §5.9 endogenous factors
09.

Standing references

Regimens' analysis and the Ask Regimens assistant draw on these authoritative sources. They are the evidence base for compounds that do not yet have a per-compound curated citation above.

Last reviewed · October 2026